Formulations containing high concentrations of VEGF receptor fusion proteins
By optimizing the composition of high-concentration VEGF receptor fusion protein formulations, including buffers, heat stabilizers, and surfactants, the problems of protein aggregation and increased viscosity at high concentrations were solved, resulting in pharmaceutically acceptable formulations with stability and efficacy suitable for intraocular injection.
Patent Information
- Application Number
- CN202411061653.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-05
- Filing Date
- 2019-05-10
- Publication Date
- 2024-11-15
AI Technical Summary
Existing technologies make it difficult to develop pharmaceutically acceptable high-concentration VEGF receptor fusion protein formulations, especially to maintain appropriate activity and delivery parameters at high concentrations, such as manufacturing and storage stability issues caused by protein aggregation and increased viscosity.
By preparing formulations containing high concentrations of VEGF receptor fusion protein, buffer solutions, heat stabilizers, viscosity reducers, and surfactants, the pH and viscosity are optimized to ensure the compatibility and stability of the formulation for intraocular injection.
It provides pharmaceutically acceptable potency, long-term stability, and viscosity suitable for intraocular injection, reducing injection volume, improving manufacturing and storage efficiency, and minimizing adverse effects on the limited volume of the eye.
Smart Images

Figure BDA0004978063890000141 
Figure BDA0004978063890000151 
Figure BDA0004978063890000531
Abstract
Description
[0001] The applicant submitted a PCT application PCT / US2019 / 031879 entitled “Preparation containing high concentration of VEGF receptor fusion protein” on May 10, 2019. The PCT application entered the Chinese national phase on December 8, 2020, with application number 201980038234.6. This application is a divisional application of the Chinese application.
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 813,882, filed on March 5, 2019; U.S. Provisional Patent Application No. 62 / 769,876, filed on November 20, 2018; U.S. Provisional Patent Application No. 62 / 752,127, filed on October 29, 2018; and U.S. Provisional Patent Application No. 62 / 669,506, filed on May 10, 2018; each of which is incorporated herein by reference in its entirety. Technical Field
[0003] Embodiments herein generally relate generally to formulations containing high concentrations of VEGF receptor fusion proteins suitable for intraocular administration. More particularly, embodiments herein provide liquid pharmaceutical formulations for intravitreal administration, wherein the formulations contain greater than 40 mg / ml of VEGF receptor fusion proteins and exhibit pharmaceutically acceptable potency, stability, viscosity, and pH.
[0004] Sequence Listing
[0005] An official copy of the sequence listing is submitted electronically with the specification through EFS-Web in the form of a sequence listing in ASCII format, with a file name of "10430P1-US_SEQ_LIST_ST25.txt", a creation date of May 9, 2018, and a size of approximately 7KB. The sequence listing contained in this ASCII formatted document is part of the specification and is incorporated herein by reference in its entirety. Background Art
[0006] The development of therapeutically useful liquid formulations requires a combination of different amounts of ingredients to provide a functional and stable delivery vehicle for the target drug. This is especially true when the drug is a protein, and further an antibody. Antibody formulations have long been a challenge for drug developers and manufacturers because antibody activity and administration generally require pharmaceutically acceptable efficacy, weight-gram molecular osmotic concentration, protein stability, viscosity, and appropriate pH. These challenges can be exacerbated when the concentration of the antibody in the formulation is high (e.g., more than 20 to 40 mg / ml of the concentration of most pharmaceutically marketed antibodies).
[0007] Higher concentrations of antibody preparations can shorten injection time, reduce injection volume, reduce antibody administration frequency and improve production efficiency and storage efficiency. However, as mentioned above, the higher the concentration of the antibody or protein, the more difficult it is to maintain the appropriate activity and delivery parameters of the preparation. In particular, high concentrations of antibodies and protein preparations often compete with increased protein aggregation and viscosity, which leads to lower overall antibody or protein efficacy, lower manufacturing stability and poor storage stability. Due to the problems associated with high concentration proteins or antibody preparations, such pharmaceutically acceptable preparations are rarely developed. This area needs to prepare high concentrations, high stability antibodies and protein preparations including appropriate effectiveness, stability, viscosity, weight-gram molecular osmotic concentration and pH value.
[0008] One such protein that requires a high concentration formulation is the vascular endothelial growth factor (VEGF) receptor fusion protein. VEGF receptor fusion proteins are used to block the function of VEGF in many ophthalmic formulations, such as (Regeneron Pharmaceuticals, Inc.) Formulations containing high concentrations of VEGF receptor fusion proteins can shorten ocular injection time, reduce injection volume, reduce the number of possible injections per administration cycle, and improve manufacturing and storage efficiency.
[0009] The present invention is directed to overcoming one or more of the problems discussed above. Summary of the invention
[0010] Various embodiments described herein include preparations containing high concentrations of proteins (e.g., suitable for intravitreal administration), particularly preparations containing high concentrations of vascular endothelial growth factor (VEGF) receptor fusion proteins. Preparations containing high concentrations of VEGF receptor fusion proteins can provide many therapeutic and economic benefits, including pharmaceutically acceptable efficacy, long-term manufacturing and storage stability, and viscosity and pH compatible with intraocular injection. Preparations containing high concentrations of VEGF receptor fusion proteins can also reduce the amount of ocular administration, which is a benefit of avoiding adverse effects on the limited volume of the eye.
[0011] Embodiments herein provide preparations with VEGF receptor fusion protein, buffer, thermal stabilizer, viscosity reducer and surfactant.In other embodiments, the preparation does not include viscosity reducer.Preparation of the present invention has pH and viscosity suitable for injection, particularly suitable for therapeutic ocular injection.
[0012] In one embodiment of the present invention, a pharmaceutical formulation of the present invention is provided, which has a VEGF receptor fusion protein, wherein the concentration of the VEGF receptor fusion protein is at least 41 mg / ml or comprises a single dose of a VEGF receptor fusion protein (which is discussed herein) at a concentration of less than about 100□l, less than about 50□l, about 50□l, about 57□l, about 60□l, about 70□l or about 75□l, a buffer, optionally a thermal stabilizer and / or a viscosity reducer, and a surfactant, wherein the pH of the formulation is about 5.0 to about 6.8 (e.g., 5.8).
[0013] In one embodiment of the invention, the VEGF receptor fusion protein concentration is about 30 mg / ml, 60 mg / ml, 114 mg / ml, 120 mg / ml or 140 mg / ml.
[0014] In one embodiment of the invention, the surfactant can be a nonionic surfactant (e.g., about 0.02% to about 0.1%; or about 0.03% (w / v)). In one embodiment of the invention, the surfactant is a nonionic surfactant having a polyoxyethylene portion, for example, polysorbate 20 (PS20), polysorbate 80 (PS80), poloxamer 188, polyethylene glycol 3350, or a mixture thereof.
[0015] In one embodiment of the invention, the buffer is a histidine-based buffer (e.g., 10 mM or 20 mM), such as histidine, histidine hydrochloride, or histidine acetate; a phosphate-based buffer, such as sodium phosphate (e.g., 10 mM); an acetate-based buffer, such as sodium acetate and acetic acid, or a citrate-based buffer, such as sodium citrate or citric acid. In one embodiment of the invention, if the buffer is a phosphate buffer, the pH is about 5.7 to about 8.0, about 5.8 to about 8.0, about 5.7 to about 7.0, about 5.8 to about 7.0, about 5.9 to about 7.0, or about 6.0 to 7.0; if the buffer is a histidine buffer, the pH is about 5.5 to about 6.5; if the buffer is a citrate buffer, the pH is about 3.0 to about 6.2 or about 5.0 to about 6.0; if the buffer is an acetate buffer, the pH is about 3.7 to about 5.6 or about 5.0 to about 6.0.
[0016] In one embodiment of the invention, the thermal stabilizer is a sugar, such as sucrose (e.g., about 2.5%, 5% or 8%, 10% or 20% (w / v), such as about 2-20%), mannitol, sorbitol or trehalose; L-proline (e.g., about 2%, 3% or 4% (w / v)); glycine (e.g., about 50 mM), glycerol, taurine (e.g., about 50 mM) or propane sulfonic acid (e.g., about 50 mM) or any combination thereof.
[0017] In some embodiments of the invention, the pharmaceutical formulations of the invention include a viscosity reducer, such as arginine hydrochloride (e.g., L-arginine monohydrochloride) (e.g., 50 mM), lysine, sodium chloride (e.g., 40 mM or 50 mM), or magnesium chloride. Alternatively, in other embodiments, the formulations of the invention specifically exclude substantially all, if not all, viscosity reducers.
[0018] In one embodiment of the invention, the pharmaceutical formulation of the invention comprises, consists of, or consists essentially of the ingredients of any of Formulations A-KKKK described herein.
[0019] In aspects herein, the pharmaceutical formulations of the invention may include a VEGF receptor fusion protein (e.g., aflibercept or conbercept) at a concentration of about 41 mg / ml to about 275 mg / ml, about 80 mg / ml to about 275 mg / ml, about 140 mg / ml to about 150 mg / ml, about 140 mg / ml to about 159 or 160 mg / ml; including about 60 mg / ml, about 80 mg / ml, about 100 mg / ml, about 113.3 mg / ml, about 114.3 mg / ml, about 120 mg / ml, about 133.3 mg / ml, about 140 mg / ml, about 150 mg / ml, about 200 mg / ml or about 250 mg / ml. In one embodiment of the invention, the formulation includes about 40 mg / ml of a VEGF receptor fusion protein.
[0020] Some aspects of the pharmaceutical formulations of the present invention include a thermal stabilizer at a concentration of about 2% (w / v) to about 9% (w / v) or about 4% (w / v) to about 9% (w / v), provided that when the thermal stabilizer is taurine or propane sulfonic acid, the concentration of the stabilizer is about 25 mM to about 100 mM, the concentration of the surfactant is about 0.02% (w / v) to about 0.1% (w / v) (e.g., about 0.03%), and the buffer is about 5 mM to about 15 mM.
[0021] The VEGF receptor fusion protein may be, for example:
[0022] Encoded by the nucleic acid sequence of SEQ ID NO: 1 or nucleotides 79 to 1374 or 79 to 1371 of SEQ ID NO: 1;
[0024] · comprising the amino acid of SEQ ID NO: 2 or amino acids 27-457 or 27-458 of SEQ ID NO: 2;
[0026] ·include:
[0027] (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO: 2;
[0028] (2) a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO: 2;
[0029] (3) a multimeric component ("FcΔC1(a)") comprising amino acids 232 to 457 or 458 of SEQ ID NO:2 (the C-terminal amino acid of SEQ ID NO:2, i.e., K458, may or may not be included in the VEGF receptor fusion protein). Note that amino acids 1 to 26 of SEQ ID NO:2 are a signal sequence;
[0030] comprising an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor (e.g., VEGFR1) and an Ig domain 3 of a second VEGF receptor (e.g., VEGFR2), optionally further comprising an Ig domain 4 of a second VEGF receptor (e.g., VEGFR2) and a multimeric component (e.g., an Fc domain of IgG);
[0031] Conbercept; or
[0032] · For Aflibercept.
[0033] VEGF Trap
[0034] atggtcagctactgggacaccggggtcctgctgtgcgcgctgctcagctgtctgcttctc
[0035] acaggatctagttccggaagtgataccggtagacctttcgtagagatgtacagtgaaatc
[0036] cccgaaattatacacatgactgaaggaagggagctcgtcattccctgccgggttacgtca
[0037] cctaacatcactgttatactttaaaaaagtttccacttgacactttgatccctgatggaaaa
[0038] cgcataatctggggacagtagaaagggcttcatcatatcaaatgcaacgtacaaagaaata
[0039] gggcttctgacctgtgaagcaacagtcaatgggcatttgtataagacaaactatctcaca
[0040] catcgacaaaccaatacaatcatagatgtggttctgagtccgtctcatggaattgaacta
[0041] tctgttggagaaaagcttgtcttaaattgtacagcaagaactgaactaaatgtggggatt
[0042] gacttcaactgggaatacccttcttcgaagcatcagcataagaaacttgtaaaccgagac
[0043] ctaaaaacccagtctgggagtgagatgaagaaatttttgagcaccttaactatagatggt
[0044] gtaacccggagtgaccaaggattgtacacctgtgcagcatccagtgggctgatgaccaag
[0045] aagaacagcacatttgtcagggtccatgaaaaggacaaaactcacacatgcccaccgtgc
[0046] ccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggac
[0047] accctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaa
[0048] gaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagaca
[0049] aagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctg
[0050] caccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctccca
[0051] gcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtac
[0052] accctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtc
[0053] aaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaac
[0054] aactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaag
[0055] ctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcat
[0056] gaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatga
[0057] (SEQ ID NO:1)
[0058] MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTEGRELVI
[0059] PCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATV
[0060] NGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDF
[0061] NWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAA
[0062] SSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
[0063] TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
[0064] LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE
[0065] LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
[0066] LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0067] (SEQ ID NO:2)
[0068] AAs 1-26 = Signal sequence
[0069] AAs 27-129 = Flt1-D2(VEGFR1-D2)
[0070] AAs 130-231 = Flk1-D3(VEGFR2-D3)
[0071] AAs 232-458 = FcΔC1
[0072] In another embodiment of the present invention, a container is provided, which comprises an aqueous solution of about 5mM to about 25mM pharmaceutically acceptable buffer, about 4% (w / v) to about 9% (w / v) of a pharmaceutically acceptable thermal stabilizer, about 0.02% (w / v) to about 0.1% (w / v) of a pharmaceutically acceptable surfactant, and about 41mg / ml to about 275mg / ml of a VEGF receptor fusion protein. When the thermal stabilizer includes taurine or propane sulfonic acid, the concentration of taurine or propane sulfonic acid is about 25mM to about 100mM. The pH of the aqueous solution is about 5.0 to about 6.8, and can be about 5.5 to about 6.2 (e.g., 5.8). In some aspects, the container is a vial or a syringe. In other aspects, the aqueous solution does not contain inorganic salts. When the thermal stabilizer is a sugar, it can be sucrose, mannitol, sorbitol or trehalose, and can be present in an amount between about 4% (w / v) and 9% (w / v); the surfactant can be a non-ionic surfactant and can contain a polyoxyethylene portion, such as polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350, at a concentration of about 0.02% to 0.1% weight per volume (w / v), more typically 0.02%-0.04% (w / v). In one embodiment of the invention, the VEGF receptor fusion protein is encoded by the nucleic acid sequence of SEQ ID NO: 1 or nucleotides 79-1374 or 79-1371 of SEQ ID NO: 1; comprises the amino acids of SEQ ID NO: 2 or amino acids 27-457 or 27-458 of SEQ ID NO: 2; comprises (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO: 2; (2) a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO: 2; and (3) a multimeric component ("FcΔC1(a)") comprising amino acids 232-457 (SEQ ID NO: 2). NO: The C-terminal amino acid of 2, i.e., K458, may or may not be included in the VEGF receptor fusion protein); comprising the immunoglobulin-like (Ig) domain 2 of a first VEGF receptor (e.g., VEGFR1) and the Ig domain 3 of a second VEGF receptor (e.g., VEGFR2), optionally also comprising the Ig domain 4 of the second VEGF receptor (e.g., VEGFR2) and a multimeric component (e.g., the Fc domain of IgG); is Conbercept or is Aflibercept.
[0073] In other embodiments, a pharmaceutical formulation of the invention is provided, which has a VEGF receptor fusion protein in an aqueous carrier, wherein the viscosity of the aqueous carrier is about 10 cP to about 15 cP at 20°C, more typically about 10 cP to 13 cP at 20°C, and most typically about 11 cP to about 12 cP at 20°C (e.g., about 6.0, 7.3, 11.5, or 12.0 cP at 20°C). In one embodiment of the invention, the viscosity is about 12 cP to about 15 cP at 20°C. The pH of the formulation can be about 5.8 to about 6.5 (e.g., about 5.8). In some cases, the formulation does not include a viscosity reducer, for example, does not include arginine hydrochloride, lysine, sodium chloride, or magnesium chloride. In other cases, the formulation includes 10 mM histidine hydrochloride or 10 mM histidine acetate. The sugar may be sucrose, mannitol, sorbitol or trehalose and may be present in an amount between about 4% (w / v) and 9% (w / v) (e.g., about 5%); the surfactant may be a nonionic surfactant and may include a polyoxyethylene moiety, such as polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350, in a concentration of about 0.02% to 0.1% weight per volume (w / v), more typically 0.02%-0.04% (w / v) (e.g., 0.03%). In addition, the formulation may further include a thermal stabilizer selected from taurine or propane sulfonic acid, in a concentration of about 25mM to about 100mM, more typically about 50mM to about 70mM. In one embodiment of the invention, the formulation comprises a VEGF receptor fusion protein, such as aflibercept (e.g., at a concentration of about 41-275 mg / ml, about 50 mg / ml, about 100 mg / ml, about 115 mg / ml, about 125 mg / ml, about 150 mg / ml, about 200 mg / ml or any "high" concentration discussed herein), about 10 mM histidine-based buffer, about 5% (w / v) sucrose, about 0.03% (w / v) nonionic surfactant, such as a polysorbate, such as polysorbate 20, and about 50 mM arginine, L-arginine or L-arginine monohydrochloride, at a pH of about 5.8.In one embodiment of the invention, the VEGF receptor fusion protein is encoded by the nucleic acid sequence of SEQ ID NO: 1 or nucleotides 79-1374 or 79-1371 of SEQ ID NO: 1; comprises the amino acids of SEQ ID NO: 2 or amino acids 27-457 or 27-458 of SEQ ID NO: 2; comprises (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO: 2; (2) a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO: 2; and (3) a multimeric component ("FcΔC1(a)") comprising amino acids 232-457 (SEQ ID NO: 2). NO: The C-terminal amino acid of 2, i.e., K458, may or may not be included in the VEGF receptor fusion protein); comprising the immunoglobulin-like (Ig) domain 2 of a first VEGF receptor (e.g., VEGFR1) and the Ig domain 3 of a second VEGF receptor (e.g., VEGFR2), optionally also comprising the Ig domain 4 of the second VEGF receptor (e.g., VEGFR2) and a multimeric component (e.g., the Fc domain of IgG); is Conbercept or is Aflibercept.
[0074] In yet another embodiment, a pharmaceutical formulation of the present invention is provided, which contains a VEGF receptor fusion protein at a concentration of about 80 mg / ml to about 275 mg / ml in a pharmaceutically acceptable buffer. In some cases, the stable pharmaceutical formulation may also contain taurine or propane sulfonic acid. The formulation can be stable for about 24-36 months at a temperature of about 2°C to about 8°C. In some cases, when stored at these temperatures and for this amount of time, the VEGF receptor fusion protein shows an increase of less than about 5% in high molecular weight species, and more generally, an increase of less than about 4.5% in high molecular weight species, an increase of less than about 4.0% in high molecular weight species, an increase of less than about 3.5% in high molecular weight species, an increase of less than about 3.0% in high molecular weight species, an increase of less than about 2.5% in high molecular weight species, an increase of less than about 2.0% in high molecular weight species and / or an increase of less than about 1.5% in high molecular weight species. In other cases, when the formulation is stored at these temperatures and for this amount of time, the VEGF receptor fusion protein shows an increase of less than 2.0% to 3.0% in high molecular weight species.
[0075] Embodiments herein may also include pharmaceutical formulations of the invention comprising aflibercept, a pH buffer solution, a sugar, and a surfactant, wherein the concentration of aflibercept is from 41 mg / ml to about 275 mg / ml. Alternatively, an embodiment may be a stable liquid pharmaceutical formulation comprising conbercept, a pH buffer solution, a sugar, and a surfactant, wherein the concentration of conbercept is from 41 mg / ml to about 275 mg / ml. The stable liquid pharmaceutical formulation may also comprise taurine or propane sulfonic acid. In some aspects, the concentration of aflibercept or conbercept is 80 mg / ml or 150 mg / ml. In other aspects, the formulation does not comprise an inorganic salt, such as sodium chloride.
[0076] Some embodiments relate to a sterile syringe such that the syringe is pre-filled with an aqueous solution having 80 mg / ml Aflibercept, Conbercept, 10 mM histidine hydrochloride, histidine acetate or sodium phosphate, 5% (w / v) sucrose, mannitol, sorbitol or trehalose, 0.03% (w / v) polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350 and 40 mM sodium chloride. Aspects herein include further adding about 25 mM to about 100 mM, more typically about 50 mM to about 70 mM taurine or propane sulfonic acid. In some aspects, the syringe is pre-filled with an aqueous solution having 80 mg / ml aflibercept, conbercept, 10 mM histidine hydrochloride, histidine acetate or sodium phosphate, 8% (w / v) sucrose, mannitol, sorbitol or trehalose, and 0.03% (w / v) polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350. Aspects herein include further adding about 25 mM to about 100 mM, more typically about 50 mM to about 70 mM taurine or propane sulfonic acid. In yet other aspects, the syringe is pre-filled with an aqueous solution having 150 mg / ml Aflibercept, Conbercept, 10 mM histidine hydrochloride, histidine acetate or sodium phosphate, 5% (w / v) sucrose, mannitol, sorbitol or trehalose, 0.03% (w / v) polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350 and 40 mM sodium chloride, pH about 6.2. Aspects herein may include further addition of taurine or propane sulfonic acid. In yet other aspects, the syringe is pre-filled with an aqueous solution having 150 mg / ml Aflibercept, Conbercept, 10 mM histidine hydrochloride, histidine acetate or sodium phosphate, 8% (w / v) sucrose, mannitol, sorbitol or trehalose, and 0.03% (w / v) polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350, pH about 6.2, and the aqueous solution does not include inorganic salts. Aspects may further include about 25 mM to about 100 mM, and more typically about 50 mM to about 70 mM taurine or propane sulfonic acid. In still other aspects, the syringe is pre-filled with an aqueous solution having 150 mg / ml aflibercept or conbercept, 10 mM sodium acetate or acetic acid, 5% (w / v) glycerol and 0.03% (w / v) polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350 and 40 mM sodium chloride, pH about 6.2. In still other aspects, the syringe is pre-filled with an aqueous solution having 150 mg / ml aflibercept or conbercept, 10 mM sodium acetate or acetic acid, 8% (w / v) glycerol and 0.03% (w / v) polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350 and 40 mM sodium chloride, pH about 6.2.
[0077] The present invention also provides a method for preparing any formulation described herein, including the step of combining each component of the formulation into a single composition. Such a method may include the step of adding the resulting formulation to a vial or injection device. Any composition that is the product of such a method also constitutes a part of the present invention. For example, embodiments herein also include a method for preparing a formulation by combining a histidine-based, citrate-based, acetate-based or phosphate-based buffer with sucrose, polysorbate 20 and VEGF receptor fusion protein; and optionally, one or more additional components, such as described herein. In some cases, the formulation is prepared to also include taurine or propane sulfonic acid, but in the absence of taurine or propane sulfonic acid, it may also not include an inorganic salt. In aspects of the present invention, the weight per volume of sucrose is about 4% to about 10%, the weight per volume of polysorbate 20 is about 0.02% to about 0.1%, and the concentration of the receptor fusion protein is about 41 mg / ml to about 275 mg / ml. Where the formulation includes taurine or propane sulfonic acid, it is present, for example, in an amount of about 25 mM to about 100 mM, but may also be included at 50 mM to 70 mM. The method may include loading a predetermined volume of the prepared formulation into a sterile syringe such that the volume has a 0.1 mg to 10 mg dose of the VEGF receptor fusion protein.
[0078] The present invention also provides a method of administering the preparation of the present invention to a subject (e.g., a human), comprising intraocular injection (e.g., intravitreal injection) of the preparation into the subject's eye. The present invention also provides a method of administering the preparation of the present invention to a subject (e.g., a human), comprising implanting an intravitreal implant comprising the preparation of the present invention into the vitreous of the subject.
[0079] Embodiments herein also include methods of treating a vascular-causing eye disease in a subject in need thereof, such as age-related macular degeneration (wet), macular edema following retinal vein occlusion, retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular edema (DME), choroidal neovascularization (CNV), iris neovascularization, neovascular glaucoma, post-operative fibrosis of glaucoma, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal neovascularization, vitreous neovascularization, corneal pannus, pterygium, vascular retinopathy, or diabetic retinopathy (e.g., non-proliferative diabetic retinopathy and / or proliferative diabetic retinopathy), by intraocular injection of at least about 2 mg (e.g., 4 mg, 6 mg, or 8 mg) of a VEGF receptor fusion protein (e.g., aflibercept or conbercept), such as any of the formulations described herein, into the eye of a subject in need thereof. In one embodiment of the invention, the injection volume is 100 microliters or less (e.g., 100 microliters, 50 microliters, or 57 microliters). The method comprises intravitreal injection of a premixed aqueous solution having a VEGF receptor fusion protein at a concentration of 41 mg / ml to about 275 mg / ml, a pharmaceutically acceptable sugar, a pharmaceutically acceptable buffer, and a pharmaceutically acceptable surfactant. Treatment methods using premixed aqueous solutions do not require dilution. In aspects of this invention, the premixed aqueous solution has a pH of about 6.0 to about 6.5 and a viscosity of about 10 cP to 13 cP.
[0080] In aspects of the method of treatment, the VEGF receptor fusion protein comprises VEGFR1R2-FcΔC1(a) encoded by the nucleic acid sequence of SEQ ID NO: 1, amino acids 27 to 129 of SEQ ID NO: 2, a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO: 2, or a multimerization component comprising amino acids 232 to 457 of SEQ ID NO: 2, or any combination thereof. In one embodiment of the invention, the VEGF receptor fusion protein is aflibercept or conbercept.
[0081] Other embodiments according to the disclosure herein will become apparent from a reading of the ensuing detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] The above and other aspects, features and advantages of the embodiments disclosed herein will become more apparent to those of ordinary skill in the art with reference to the accompanying drawings.
[0083] Figure 1AFigure 1 is a graph determining the stability of VEGF receptor fusion protein (aflibercept) over the course of 36 months at 2°C to 8°C for four different formulations (B, H, D, and G). The stability of the VEGF receptor fusion protein was tested using size exclusion ultra-performance liquid chromatography (SE-UPLC) to identify the formation of high molecular weight (HMW) species, a sign of protein degradation.
[0084] Figure 1B Also a graph determining the stability of VEGF receptor fusion protein (aflibercept) over the course of 36 months at 2° C. to 8° C. for four formulations (B, H, D, and G). The stability of the VEGF receptor fusion protein was tested using SE-UPLC to identify the percentage of the major species in each formulation.
[0085] Figure 1C is a bar graph showing the formation of VEGF receptor fusion protein charge variants in four formulations (B, H, D, and G) over the course of 36 months at 2°C to 8°C. The levels of acidic species were tested at manufacturing (0.0), 12 months, 24 months, and 36 months using imaging capillary isoelectric focusing (iCIEF).
[0086] Figure 1D is a bar graph showing the formation of VEGF receptor fusion protein charge variants in four formulations (B, H, D, and G) over the course of 36 months at 2°C to 8°C. The major species of ingredients were tested at manufacturing (0.0), 12 months, 24 months, and 36 months using iCIEF.
[0087] Figure 2A is a graph showing the stability of 150 mg / ml VEGF receptor fusion protein (aflibercept) in 10 mM sodium phosphate, 8% (w / v) sucrose and 0.03% polysorbate 20 (w / v) formulation pH 6.2 (with and without L-arginine monohydrochloride) during 28 days at 37° C. The stability of the VEGF receptor fusion protein was tested using SE-UPLC to identify the formation of HMW species.
[0088] Figure 2B is a graph showing the stability of 150 mg / ml VEGF receptor fusion protein in 10 mM sodium phosphate, 8% (w / v) sucrose and 0.03% polysorbate 20 (w / v) formulation pH 6.2 (with and without L-arginine monohydrochloride) over the course of 28 days at 37° C. The stability of the VEGF receptor fusion protein was tested using SE-UPLC to identify the percentage of the major species in each formulation.
[0089] Figure 3Ais a bar graph showing the viscosity of 10 mM sodium phosphate buffered formulations with 155 mg / ml VEGF receptor fusion protein without salt, with 100 mM arginine, 200 mM arginine, 50 mM lysine, 200 mM lysine, 50 mM sodium chloride or 100 mM sodium chloride. Viscosity is measured in cP at 20°C.
[0090] Figure 3B is a bar graph showing the viscosity of 10 mM histidine buffered formulations with 155 mg / ml VEGF receptor fusion protein without salt, with 100 mM arginine, 200 mM arginine, 50 mM lysine, 200 mM lysine, 50 mM sodium chloride or 100 mM sodium chloride. Viscosity is measured in cP at 20°C.
[0091] Figure 4A The results are shown in the presence and absence of 50 mM L-arginine monohydrochloride at 5°C for 12 months in 10 mM sodium phosphate, 8% (w / v) sucrose and 0.03% (w / v) polysorbate 20, pH 6.2.
[0092] Figure 3. Stability of VEGF receptor fusion protein at 150 mg / ml. VEGF receptor fusion protein at 150 mg / ml. The stability of VEGF receptor fusion protein was tested using SE-UPLC to identify the formation of HMW species.
[0093] Figure 4B Graph showing the stability of 150 mg / ml VEGF receptor fusion protein in 10 mM sodium phosphate, 8% (w / v) sucrose and 0.03% (w / v) polysorbate 20, pH 6.2 (with and without 50 mM L-arginine monohydrochloride) at 5°C for 12 months. The VEGF receptor fusion protein was 150 mg / ml. The stability of the VEGF receptor fusion protein was tested using SE-UPLC to identify the percentage of the major species in each formulation.
[0094] Figure 5 is a graph showing the viscosity of formulations under two buffer conditions (10 mM phosphate buffer or 10 mM histidine buffer) at 20°C. The VEGF receptor fusion protein concentration varied from 10 mg / ml to 170 mg / ml. The viscosity is in mPa-S.
[0095] Figure 6 Dynamic light scattering screens of various formulation conditions are shown, each with 2 to 10 mg / ml protein.Diffusion interaction parameters indicate that taurine and PSA (propane sulfonic acid) improve the Kd.
[0096] Figure 7is a graph of the percentage of high molecular weight (HMW) species over time in formulations F1-F9 (formulations WW-EEE) as measured by size exclusion ultra performance liquid chromatography (SE-UPLC) after 6 months storage at 5° C. Formulations F1-F9 are listed in Table 7-1 herein.
[0097] Figure 8 (AB) Percentage of high molecular weight species measured by SE-UPLC after storage at 5°C for 3 months (A) or incubation at 37°C for 28 days (B). Formulations F1-F4 (EEE, SSS, CCC (140 mg / ml) and TTT) are listed in Table 8-1 below.
[0098] Fig. 9 The viscosity (cp) at 20° C. is shown for Formulations F1-F12 at the initial time point. Formulations F1-F12 are listed in Table A below.
[0099] Table A. Formulations F1-F12.
[0100]
[0101]
[0102] Fig.10 The osmolality (mmol / Kg) of Formulations F1-F12 (listed in Table A herein) is shown.
[0103] FIG. 11 (AB) Percentage of high molecular weight species over time in formulations F1-F6 (formulations GGG, HHH, III, JJJ, LLL, and KKK) measured by SE-UPLC after storage at 37° C. for up to 28 days (A) or at 5° C. for up to 3 months (B).
[0104] Fig.12 The dynamic light scattering (diffusion coefficient (cm)) at the initial time point of the formulations shown in Table 9-3 (GGG-RRR) is shown. 2 / s), radius (nm) and %Pd).
[0105] FIG13 shows baseline FA images and OCT (30 degree lens) of two different rabbits (326-OS and 329-OD) before aflibercept administration (OD = oculus dexter (right eye); OS = oculus sinister (left eye)). (A) FA image of the left eye of rabbit 326; (B) OCT image of the left eye of rabbit 326; (c) FA image of the right eye of rabbit 329; (D) OCT image of the right eye of rabbit 329.
[0106] Figure 14 (AF) shows the rabbit FA images on day 1 (A), day 7 (B), and day 14 (C) and the time course of OCT on day 1 (D), day 7 (E), and day 14 (F) of a rabbit (326-OS) administered with histidine buffer formulation (30 degree lens) (7 mg / eye).
[0107] Figure 15 (AH) shows rabbit FA images of a rabbit (326-OS) administered with a histidine buffer formulation (55 degree lens) (7 mg / eye) at 3 weeks (A), 4 weeks (B), 7 weeks (C) and 8 weeks (D); and the OCT time course at 3 weeks (E), 4 weeks (F), 7 weeks (G) and 8 weeks (H).
[0108] Figure 16 (AF) shows the time course of rabbit FA images at day 1 (A), week 1 (B), and week 2 (C) and OCT at day 1 (D), week 1 (E), and week 2 (F) of a rabbit (329-OS) administered phosphate buffer formulation (30 degree lens) (7 mg / eye).
[0109] Figure 17 (AH) shows the time course of rabbit FA images at 3 weeks (A), 4 weeks (B), 7 weeks (C) and 8 weeks (D) and OCT at 3 weeks (E), 4 weeks (F), 7 weeks (G) and 8 weeks (H) of a rabbit (329-OS) administered phosphate buffer formulation (55 degree lens) (7 mg / eye).
[0110] Figure 18 (AB) shows the purity (percent of native species) (A) and percentage of high molecular weight (HMW) species (B) in formulation UUU-BBBB over time at 37°C (up to one month) (see Table 11-1), as analyzed by SE-UPLC.
[0111] FIG. 19 (AE) shows stability and purity analysis of formulations having 114.3 mg / mL VEGF Trap (aflibercept) formulated in 10 mM histidine, pH 5.8, 5% sucrose, 0.03% polysorbate 20, 50 mM arginine-HCl by size exclusion chromatography to determine the percentage of: (i) high molecular weight species (HMW) after incubation for up to 2 months at 5°C or 37°C (A) and (ii) major species (main peak) after incubation for up to 2 months at 5°C or 37°C (B); and by microfluidic imaging to determine the presence of microscopically visible particles after incubation for up to 28 days at 37°C (C), by particle light obscuration analysis to determine the presence of microscopically visible particles after incubation for up to 28 days at 37°C (D), and by microscopy to determine microscopically visible particles after incubation for up to 28 days at 37°C (E).
[0112] Figure 20 shows the stability and purity analysis of Formulation CCC with 80, 100, 120 or 140 mg / ml Aflibercept as determined by SE-UPLC for the percentage of high molecular weight species (HMW) after incubation at 2-8°C for up to 6 months (A) or at 37°C for up to 28 days (B).
[0113] Fig.21 Shown are the percentages of rabbit eyes tested with complete leakage inhibition over time when 500 micrograms or 2 mg of aflibercept were administered (Gehan-Breslow-Wilcoxon test (P 0.0453)). DETAILED DESCRIPTION
[0114] The present invention provides formulations with high concentrations of VEGF receptor fusion proteins (e.g., aflibercept) that exhibit excellent functional and storage characteristics despite significant technical hurdles. For example, a common method for identifying suitable excipients for formulations containing polypeptide drugs (e.g., VEGF receptor fusion proteins) is by evaluating the stability of the polypeptide under accelerated stress conditions, such as high temperatures (e.g., 37° C.). Excipients that are not suitable under non-stress conditions (e.g., low temperatures, such as 5° C.) often cause undesirable effects (e.g., protein aggregation) under stress in a short period of time. This method is common in the biotechnology and pharmaceutical industries because it accelerates the elimination of excipients that are unlikely to stabilize the drug product. See, e.g., Magari, Assessing Shelf Life Using Real-Time and Accelerated Stability Tests, Biopharm Intl. 16(11):36-48(2003). In some cases, the product can be released based on accelerated stability data, but this must be performed simultaneously with real-time shelf life analysis (non-accelerated). Magari (2003) and FDA, Guidelines for Submitting Documentation for the Stability of Human Drugs and Biologics, Rockville, MD (1987). However, here, at 5°C, the presence of arginine in the histidine formulation is stable, although it appears that arginine tends to reduce stability under temperature stress (37°C). See Figure 8 (AB). This property of the formulation described herein will bring technical difficulties, which guides practitioners not to choose arginine; therefore, practitioners are unlikely to choose arginine as an excipient. However, the formulation proposed herein overcomes technical obstacles such as this to obtain a formulation with high stability. The formulation of VEGF trap in histidine buffer also results in a beneficial reduction in viscosity relative to the viscosity observed for phosphate buffer formulations. Since small needle holes are preferred for intravitreal injection (due to reduced patient discomfort and eye trauma), relatively low viscosities are desired. Lower viscosity formulations require less force to push the formulation through the needle, making it easier for the treating physician to inject the formulation through the needle. Additionally, formulations containing histidine and arginine were well tolerated in rabbit eyes.
[0115] Reference will now be made in detail to representative embodiments. It should be understood that the following description is not intended to limit the embodiments to a preferred embodiment. Instead, they are intended to cover substitutions, modifications and equivalents that may be included within the spirit and scope of the described embodiments defined in the appended claims.
[0116] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art to which the present disclosure belongs. As used herein, when used to refer to a specific listed value, the term "about" means that the numerical value may differ from the cited value by no more than 1%. Thus, for example, as used herein, the expression "about 100" includes 99 and 101 and all values therebetween (e.g., 99.1%, 99.2%, 99.3%, 99.4%, etc.).
[0117] In one embodiment of the present invention, the pharmaceutical formulation of the present invention complies with the USP for small volume injection (SVP) of ocular solution <789> , for example, each ml contains less than about 50 diameter > 10□m particles; each ml contains less than about 5 diameter > 25□m; or less than about 2 diameter particles per ml > 50□m particles.
[0118] Note that for purposes herein, "intravitreal injection" refers to injection into the vitreous of the eye (near the retina at the back of the eye). The expression "suitable for intravitreal administration," "suitable for intravitreal injection," and the like means that the formulation in question can be safely injected into the vitreous of a subject's eye without causing any adverse reactions known to be associated with intravitreal injections of EYLEA.
[0119] The term "pharmaceutical formulation" herein refers to a formulation including a pharmaceutically acceptable carrier, for example, for administering a VEGF receptor fusion protein (eg, aflibercept or conbercept) to a subject for therapeutic / medical use.
[0120] The term "pharmaceutically acceptable" refers to formulations that are, within the scope of sound medical judgment, suitable for administration to the eye.
[0121] The term "subject" herein refers to any mammalian (eg, rabbit, mouse, rat, or monkey) subject, particularly a human, for whom diagnosis, prognosis, or treatment with the formulations described herein is desired.
[0122] The term "aqueous" formulation refers to a formulation that includes water.
[0123] The term "treat" or "treatment" refers to a therapeutic measure that reverses, stabilizes or eliminates an undesirable disease or condition (e.g., angiogenic eye disease or cancer), such as by causing regression, stabilization or elimination of one or more symptoms or signs of such a disease or condition to any clinically measurable extent (e.g., with respect to angiogenic eye disease), by reducing or maintaining the diabetic retinopathy severity score (DRSS), by improving or maintaining visual acuity (e.g., best corrected visual acuity, e.g., measured by increasing ETDRS letters), increasing or maintaining visual field and / or reducing or maintaining central retinal thickness, and, in the case of cancer, stopping or reversing the growth, survival and / or metastasis of cancer cells in a subject. Typically, the therapeutic measure is to administer one or more therapeutically effective amounts of a VEGF receptor fusion protein to a subject suffering from a disease or condition.
[0124] "Prevent" or "prevention" refers to preventive measures to hinder the development of an undesirable disease or condition (eg, angiogenic eye disease).
[0125] SE-UPLC can be used in the present invention to quantify the presence of high molecular weight species in a formulation. SE refers to size exclusion chromatography. UPLC refers to ultra performance liquid chromatography. Suitable SE columns that can be used in a UPLC system to characterize such HMW species of VEGF receptor fusion proteins (e.g., aflibercept or conbercept) in a formulation are capable of resolving molecules with a molecular weight range of about 10,000-450,000 Daltons. For example, see ACQUITY UPLC Protein BEH SEC Chromatographic columns. In one embodiment of the invention, two such columns are connected in series when quantifying HMW species in a formulation. UPLC has improved sensitivity and resolution compared to HPLC (high performance liquid chromatography). The instrument used by UPLC operates at high pressure and uses finer particles (typically less than 2.5 μm) than those used in HPLC. In addition, UPLC flow phases are operated at high linear speeds compared to HPLC.
[0126] Embodiments herein include formulations comprising high concentrations (e.g., about 60 mg / ml, about 80 mg / ml, about 90 mg / ml, about 100 mg / ml, about 113.3 mg / ml, about 114.3 mg / ml, about 120 mg / ml, about 133.3 mg / ml, about 140 mg / ml, about 150 mg / ml, about 200 mg / ml, or about 250 mg / ml) of VEGF receptor fusion proteins (e.g., Aflibercept or Conbercept). Suitable formulations included herein include high concentrations of VEGF receptor fusion proteins, buffers, thermal stabilizers, and surfactants. In some aspects, suitable formulations also include viscosity reducers. In other aspects, suitable formulations substantially do not include all viscosity reducers. Typical formulations have a pH of about 5.0 to about 6.8 (e.g., 5.8), but may include any pH that can be used to administer VEGF receptor fusion proteins to the eye of a subject.
[0127] The present invention includes formulations comprising a VEGF receptor fusion protein (e.g., aflibercept or conbercept) in combination with one or more other therapeutic agents (e.g., an Ang-2 inhibitor (e.g., an anti-ANG2 antibody or antigen-binding fragment thereof) or nesvacumab), a Tie-2 receptor activator, an anti-PDGF, PDGF receptor or PDGF receptor beta antibody or antigen-binding fragment thereof and / or other VEGF antagonists, such as bevacizumab, ranibizumab, pegaptanib or a soluble form of human vascular endothelial growth factor receptor 3 (VEGFR-3) comprising extracellular domains 1-3, expressed as an Fc fusion protein), and methods of prevention or treatment comprising administering such formulations as described herein. In one embodiment of the present invention, the formulation of the present invention comprises a VEGF receptor fusion protein, such as aflibercept, but does not include any other therapeutic agent (e.g., which is an antibody or antigen-binding fragment thereof).
[0128] The term "in combination with" means that the formulation and other therapeutic agents can be formulated into a single composition, for example, for simultaneous delivery, or separately formulated into two or more compositions (e.g., a kit). The other therapeutic agent itself can be formulated into its own pharmaceutical formulation. Each can be administered to the subject at the same time as the other or at a different time than the other; for example, each administration can be given non-simultaneously (e.g., separately or sequentially) within a given time interval. In addition, the formulation and other therapeutic agents can be administered to the subject by the same or different routes.
[0129] In one embodiment of the invention, the formulation of the invention comprises any one or more of sodium sulfate (e.g., 50 mM); sodium thiocyanate (e.g., 50 mM); sodium citrate (e.g., 40 mM); glycine (e.g., 50 mM); sodium chloride (e.g., 50 mM); lysine (e.g., 50 mM); sodium aspartate (e.g., 50 mM); and / or sodium glutamate (e.g., 50 mM). For example, in one embodiment, the formulation comprises a combination of sodium citrate (e.g., 50 mM) and arginine hydrochloride (e.g., 50 mM); glycine (e.g., 50 mM) and arginine hydrochloride (e.g., 50 mM); sodium aspartate (e.g., 50 mM) and arginine hydrochloride (e.g., 50 mM); or sodium glutamate (e.g., 50 mM) and arginine hydrochloride (e.g., 50 mM).
[0130] VEGF receptor fusion proteins and other VEGF inhibitors
[0131] For the purposes of this document, a "VEGF receptor fusion protein" refers to a molecule comprising one or more VEGF receptors or domains thereof fused to another polypeptide that interferes with the interaction between VEGF and a native VEGF receptor, e.g., wherein two such fusion polypeptides bind to form a homodimer or other multimer. Such a VEGF receptor fusion protein may be referred to as a "VEGF-Trap" or "VEGF Trap." VEGF receptor fusion proteins falling within this definition within the scope of the present disclosure include chimeric polypeptides comprising two or more immunoglobulin (Ig)-like domains of a VEGF receptor, e.g., VEGFR1 (also known as Flt1) and / or VEGFR2 (also known as Flk1 or KDR), and may also comprise a multimerization domain (e.g., an Fc domain).
[0132] An exemplary VEGF receptor fusion protein is the molecule designated VEGF1R2-FcΔC1(a), which is encoded by the nucleic acid sequence of SEQ ID NO: 1, or nucleotides 79-1374 or 79-1371 thereof.
[0133] VEGF1R2-FcΔC1(a) contains three components:
[0134] (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO: 2;
[0135] (2) a VEGFR2 component comprising amino acids 130 to 231 of SEQ ID NO: 2; and
[0136] (3) A multimeric component ("FcΔC1(a)") comprising amino acids 232 to 457 of SEQ ID NO:2 (the C-terminal amino acid K458 of SEQ ID NO:2 may or may not be included in the VEGF receptor fusion protein, see U.S. Pat. Nos. 7,396,664 or 7,354,579, which are incorporated herein for all purposes). Note that amino acids 1 to 26 of SEQ ID NO:2 are a signal sequence.
[0137] In one embodiment of the invention, the VEGF receptor fusion protein comprises amino acids 27-458 or 27-457 of SEQ ID NO:2.
[0138] In one embodiment of the present invention, the VEGF receptor fusion protein comprises
[0139] (1) the immunoglobulin-like (Ig) domain 2 of a first VEGF receptor (e.g., VEGFR1), and
[0140] (2) Ig domain 3 of a second VEGF receptor (e.g., VEGFR2),
[0141] (3) and optionally, further comprising an Ig domain 4 of a second VEGF receptor (e.g., VEGFR2) and
[0142] (4) Multimeric components (e.g., the Fc domain of IgG).
[0143] For example, in one embodiment of the invention, the VEGF receptor fusion protein has the following arrangement of the domains:
[0144] [VEGFR1 Ig domain 2]-[VEGFR2 Ig domain 3]-[MC] (e.g., a homodimer thereof)
[0145] or
[0146] ·[VEGFR1 Ig domain 2]-[VEGFR2 Ig domain 3]-[VEGFR2 Ig domain 4]-
[0147] [MC] (eg, a homodimer thereof).
[0148] In one embodiment of the invention, the VEGF receptor fusion protein is a VEGF microtrap, which is a VEGF Trap molecule with a truncated multimeric component (e.g., Fc), for example, wherein the microtrap still includes the Fc hinge region. See, for example, WO2005 / 00895 or U.S. Pat. No. 7,396,664.
[0149] Note that the present disclosure also includes within its scope high concentration formulations that include VEGF binding molecules and anti-VEGF antibodies and antigen-binding fragments thereof instead of VEGF receptor fusion proteins,
[0150] bevacizumab (e.g., at a concentration of about 80-90 or 88 mg / ml),
[0151] ranibizumab (e.g. at a concentration of about 20-40 mg / ml, e.g. 21-35, 21 or 35 mg / ml),
[0152] anti-VEGF aptamers, such as pegaptanib (e.g. pegaptanib sodium),
[0153] Single chain (such as V L -V H ) an anti-VEGF antibody, such as brolucizumab (e.g., at a concentration of about 200-400 or 200, 210, 400 or 420 mg / ml),
[0154] Anti-VEGF DARPin, such as Abicipar Pegol DARPin (e.g., at a concentration of about 70-140
[0155] 70 or 140 mg / ml), or
[0156] - A bispecific anti-VEGF antibody, for example, which can also bind to ANG2, such as RG7716 (e.g., at a concentration of about 100-400, 100, 105, 400 or 420 mg / ml).
[0157] To minimize repetitiveness of the embodiments discussed herein, it is contemplated that the scope of the invention includes embodiments in which any formulation discussed herein includes an anti-VEGF antibody or antibody fragment at any concentration discussed herein or other VEGF binding molecule discussed herein (e.g., substituted with an anti-VEGF DARPin) in place of a VEGF receptor fusion protein. For example, the invention includes formulations with 35 or 80 mg / ml ranibizumab, a buffer, a thermal stabilizer, a viscosity reducer, and a surfactant.
[0158] DARPins are designed ankyrin repeat proteins. DARPins typically contain three to four tightly packed repeats of about 33 amino acid residues, each of which contains a beta turn and two antiparallel alpha helices. This rigid framework provides protein stability while enabling the presentation of the variable regions, which typically contain six amino acid residues per repeat, for target recognition.
[0159] An "anti-VEGF" antibody or antigen-binding fragment of an antibody is one that specifically binds to VEGF.
[0160] Exemplary VEGF receptor fusion proteins include aflibercept ( Regeneron Pharmaceuticals, Inc.) or Conbercept (commercially sold by Chengdu Kanghong Biotechnology Co., Ltd.). See International Patent Application Publication No. WO2005 / 121176 or WO2007 / 112675. The terms "aflibercept" and "conbercept" include biosimilar forms thereof. Reference to a biosimilar form of a product (e.g., aflibercept) generally refers to a product comprising the same amino acid sequence, but includes products that are biosimilar under the U Biologics Price Competition and Innovation Act.
[0161] The pharmaceutical preparations of the present invention are "high concentrations". The high concentration pharmaceutical preparations of the present invention comprise a VEGF receptor fusion protein at a concentration of at least 41 mg / ml, at least 80 mg / ml, at least 100 mg / ml, at least 125 mg / ml, at least 140 mg / ml, at least 150 mg / ml, at least 175 mg / ml, at least 200 mg / ml, at least 225 mg / ml, at least 250 mg / ml, or at least 275 mg / ml. Alternatively, "high concentration" may refer to a VEGF receptor fusion protein comprising a preparation at a concentration of about 140 mg / ml to about 160 mg / ml, at least about 140 mg / ml but less than 160 mg / ml, about 41 mg / ml to about 275 mg / ml, about 70 mg / ml to about 75 mg / ml, or about 80 mg / ml to about 250 mg / ml. In some aspects, the concentration of the VEGF receptor fusion protein in the formulation is about any of the following concentrations: 41 mg / ml; 42 mg / ml; 43 mg / ml; 44 mg / ml; 45 mg / ml; 46 mg / ml; 47 mg / ml; 48 mg / ml; 49 mg / ml; 50 mg / ml; 51 mg / ml; 52 mg / ml; 53 mg / ml; 54 mg / ml; 55 mg / ml; 56 mg / ml; 57 mg / ml; 58 mg / ml; 59 mg / ml; 60 mg / ml; 61 mg / ml; 62 mg / ml; 63 mg / ml; 64 mg / ml; 65 mg / ml; 66 mg / ml; 67 mg / ml; 68 mg / ml; 69 mg / ml; 70 mg / ml; 71 mg / ml; 72 mg / ml; 73 mg / ml; 74 mg / ml; 75 mg / ml; 76 mg / ml; 77 mg / ml; 78 mg / ml; 79 mg / ml; 80 mg / ml; 81 mg / ml; 82 mg / ml; 83 mg / ml; 84 mg / ml; 85 mg / ml; 86 mg / ml; 87 mg / ml; 88 mg / ml; 89 mg / ml; mg / ml; 98 mg / ml; 99 mg / ml; 100 mg / ml; 101 mg / ml; 102 mg / ml; 103 mg / ml; 104 mg / ml; 105 mg / ml; 106 mg / ml; 107 mg / ml; 108 mg / ml; mg / ml; 113.3 mg / ml; 114 mg / ml;114.1mg / ml;114.2 mg / ml;114.3 mg / ml;114.4 mg / ml;114.5 mg / ml;114.6 mg / ml,114.7 mg / ml,114.8mg / ml;114.9 mg / ml;115 mg / ml;116 mg / ml;117 mg / ml;118 mg / ml;119mg / ml;120 mg / ml;121 mg / ml;122 mg / ml;123 mg / ml;124 mg / ml;125mg / ml;126 mg / ml;127mg / ml;128 mg / ml;129 mg / ml;130 mg / ml;131mg / ml;132 mg / ml;133 mg / ml;133.3 mg / ml;133.4 mg / ml,134 mg / ml;135mg / ml;136 mg / ml;137 mg / ml;138 mg / ml;139 mg / ml;140mg / ml;141mg / ml;142 mg / ml;143 mg / ml;144 mg / ml;145 mg / ml;146 mg / ml;147mg / ml;148mg / ml;149 mg / ml;150 mg / ml;151 mg / ml;152 mg / ml;153mg / ml;154mg / ml;155 mg / ml;156mg / ml;157mg / ml;158 mg / ml;159 mg / ml;160 mg / ml;161 mg / ml;162 mg / ml;163 mg / ml;164 mg / ml;165 mg / ml;166mg / ml;167 mg / ml;168 mg / ml;169 mg / ml;170 mg / ml;171 mg / ml;172mg / ml;173 mg / ml;174 mg / ml;175 mg / ml;176 mg / ml;177 mg / ml;178mg / ml;179mg / ml;180 mg / ml;181 mg / ml;182 mg / ml;183 mg / ml;184mg / ml;185 mg / ml;186 mg / ml;187 mg / ml;188 mg / ml;189 mg / ml;190mg / ml;191mg / ml;192mg / ml;193mg / ml;194mg / ml;195mg / ml;196mg / ml;197mg / ml;198mg / ml;199mg / ml;200mg / ml;201mg / ml;202mg / ml;203mg / ml;204mg / ml;205mg / ml; 206mg / ml; 207mg / ml; 208mg / ml; 209mg / ml; 210mg / ml; 211mg / ml; 212mg / ml; 213mg / ml ;214mg / ml; 215mg / ml; 216mg / ml; 217mg / ml; 218mg / ml; 219mg / ml; 220mg / ml; 221mg / ml; 222mg / m l; 223mg / ml; 224mg / ml; 225mg / ml; 226mg / ml; 227mg / ml; 228mg / ml; 229mg / ml; 230mg / ml; 231mg / ml; 232mg / ml; 233mg / ml; 234mg / ml; 235mg / ml; 236mg / ml; 237mg / ml; 238mg / ml; 239mg / ml; 240mg / ml; 241mg / ml; 242mg / ml; 243mg / ml; 244mg / ml; 245mg / ml; 246mg / ml; 247mg / ml; 248mg / ml; 249m g / ml; 250mg / ml; 251mg / ml; 252mg / ml; 253mg / ml; 254mg / ml; 255mg / ml; 256mg / ml; 257mg / ml; 258 100mg / ml; 259mg / ml; 260mg / ml; 261mg / ml; 262mg / ml; 263mg / ml; 264mg / ml; 265mg / ml; 266mg / ml; 267mg / ml; 268mg / ml; 269mg / ml; 270mg / ml; 271mg / ml; 272mg / ml; 273mg / ml; 274mg / ml; or 275mg / ml. Other VEGF receptor fusion protein concentrations are contemplated herein, provided that the concentration functions according to the embodiments herein. ;
[0162] In one embodiment of the invention, the concentration of the pharmaceutical formulation of the invention is such that it contains about 4, 6, 8, 10, 12, 14, 16, 18 or 20 mg of a VEGF receptor fusion protein (e.g., aflibercept), or an amount of such protein in any acceptable dose thereof discussed herein, of about 100 □ l or less, about 75 □ l or less or about 70 □ l or less, such as about 50 □ l; 51 □ l; 52 □ l; 53 □ l; 54 □ l; 55 □ l
[0163] □l;56□l;57□l;58□l;59□l;60□l;61□l;62□l;63□l;64□l;65□l;66□l;67□l;68□l;69□l;70□l;71□l;72□l;73□l;74□l;75□l;76□l;77□l;78□l;79□l;80□l;81□l;82□l;83□l;84□l;85□l;86□l;87□l;88□l;89□l;90□l;91□l;92□l;93□l;94□l;95□l;96□l;97□l;98□l;99□l; or 100□l.
[0164] The invention includes any of the formulations listed herein under "Illustrative Formulations," but wherein the concentration of VEGF receptor fusion protein (e.g., aflibercept) is substituted for the concentrations set forth in this section ("VEGF Receptor Fusion Proteins and Other VEGF Inhibitors").
[0165] Buffer
[0166] Buffer used herein refers to a solution that resists pH changes by using an acid-base conjugate. Buffer can maintain pH in the range of about 5.0 to about 6.8, and more generally, in the range of about 5.8 to about 6.5, and most generally, in the range of about 6.0 to about 6.5. In some cases, the pH of the formulation of the present invention is about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7 or about 6.8. Examples of buffers used in the formulations herein include buffers based on histidine, such as histidine, histidine hydrochloride and histidine acetate. The buffer contained in the formulations herein can alternatively be a phosphate-based buffer, such as sodium phosphate, an acetate-based buffer, such as sodium acetate or acetic acid, or a citrate-based buffer, such as sodium citrate or citric acid. It is also recognized that the buffer can be the above-mentioned mixture, as long as the buffer can buffer the formulation within the above-mentioned pH range. In some cases, the buffer is about 5mM to about 25mM, or more generally about 5mM to about 15mM. The buffer can be about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, about 15mM, about 16mM, about 17mM, about 18mM, about 19mM, about 20mM, about 21mM, about 22mM, about 23mM, about 24mM or about 25mM.
[0167] In one embodiment of the present invention, histidine and histidine monohydrochloride are used to prepare a histidine-based buffer.
[0168] Surfactants
[0169] Surfactant used herein refers to the component that protects the VEGF receptor fusion protein of higher concentration from various surface and interface induced stress.Like this, surfactant can be used to limit or minimize the aggregation of VEGF receptor fusion protein, and promote the solubility of protein.It has been shown that suitable surfactant is nonionic herein, and can include surfactant with polyoxyethylene part.Exemplary surfactant in this class includes: polysorbate 20, polysorbate 80, poloxamer 188, polyethylene glycol 3350 and mixture thereof.Surfactant in preparation can exist with about 0.02% to about 0.1% (w / v) per volume weight, and more generally about 0.02% to about 0.04% (w / v). In some cases, the surfactant is about 0.02% (w / v), about 0.03% (w / v), about 0.04% (w / v), about 0.05% (w / v), about 0.06% (w / v), about 0.07% (w / v), about 0.08% (w / v), about 0.09% (w / v), or about 0.1% (w / v).
[0170] Heat Stabilizer
[0171] Thermostats used herein refer to components that provide thermal stability for thermal denaturation of VEGF receptor fusion proteins and prevent the effectiveness or activity loss of VEGF receptor fusion proteins. Suitable thermostabilizers include sugars, and may be sucrose, trehalose, sorbitol or mannitol, or may be amino acids, such as L-proline, L-arginine (e.g., L-arginine hydrochloride) or taurine. In addition, thermostabilizers may also include substituted acrylamide or propane sulfonic acid, or may be compounds such as glycerol.
[0172] In some cases, the preparation herein includes sugar and taurine, sugar and amino acid, sugar and propane sulfonic acid, sugar and taurine, glycerol and taurine, glycerol and propane sulfonic acid, amino acid and taurine, or amino acid and propane sulfonic acid. In addition, the preparation can include sugar, taurine and propane sulfonic acid, glycerol, taurine and propane sulfonic acid, and L-proline, taurine and propane sulfonic acid.
[0173] The embodiments herein generally have a thermal stabilizer present alone, each independently present at the following concentrations, or present in a total concentration combination of about 2% (w / v) to about 10% (w / v) or about 4% (w / v) to about 10% (w / v), or about 4% (w / v) to about 9% (w / v), or about 5% (w / v) to about 8% (w / v). The concentration of the thermal stabilizer in the formulation can be about 2% (w / v), about 2.5% (w / v), about 3% (w / v), about 4% (w / v), about 5% (w / v), about 6% (w / v), about 7% (w / v), about 8% (w / v), about 9% (w / v), about 10% (w / v) or about 20% (w / v).
[0174] With respect to taurine and propane sulfonic acid, in one embodiment of the invention, these thermal stabilizers may be present in the formulation in an amount of about 25 mM to about 100 mM, more typically about 50 mM to about 75 mM (compared to other thermal stabilizers).
[0175] Viscosity reducer
[0176] Viscosity reducers are generally used to reduce or prevent protein aggregation.Viscosity reducers for this paper include: sodium chloride, magnesium chloride, D- or L-arginine (for example, monohydrochloric acid L-arginine), lysine or its mixture.When present herein, viscosity reducers can be with about 10mM to about 100mM, and more typically about 30mM to about 75mM, and even more typically about 40mM to about 70mM amount exists.In some cases, viscosity reducers exist with following: about 10mM, about 15mM, about 20mM, about 25mM, about 30mM, about 35mM, about 40mM, about 45mM, about 50mM, about 55mM, about 60mM, about 65mM, about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM or about 100mM.
[0177] Viscosity of preparation
[0178] The preparations according to the embodiments herein can also have a pharmaceutically acceptable viscosity for intraocular administration such as intravitreal injection. Viscosity generally refers to the measure of the resistance of a fluid deformed by shear stress or tensile stress (usually measured by techniques known in the art such as a viscometer or rheometer). The typical viscosity of the preparations according to the embodiments herein is about 5.0 cP (centipoise) to about 15 cP, about 11 cP to about 14 cP, about 12 cP to about 15 cP or about 11 cP to about 12 cP. Thus, the viscosity of the formulations herein may be about 5.0 cP, about 6.0, about 7.1 cP, about 7.2 cP, about 7.3 cP, about 7.4 cP, about 7.5 cP, about 7.6 cP, about 10 cP, about 10.5 cP, about 11.0 cP, about 11.5 cP, about 12.0 cP, about 12.5 cP, about 13.0 cP, about 13.5 cP, about 14.0 cP, about 14.5 cP, or about 15.0 cP (e.g., measured at 20°C).
[0179] Various embodiments herein do not need to include inorganic salts or other viscosity reducers to maintain these highly useful viscosities. Typically, high concentration protein solutions require viscosity reducers to avoid protein aggregation and higher viscosity, which makes the preparation difficult to inject into the vitreous and reduces the effectiveness of VEGF receptor fusion protein. Like this, embodiments herein include preparations that are substantially free of or do not add sodium chloride (NaCl), magnesium chloride (MgCl2), hydrochloric acid D- or L-arginine, lysine or other viscosity reducers.
[0180] Preparation weight gram molecular osmotic concentration
[0181] Osmolality is a key attribute of an injectable formulation. It is desirable to have a product that matches physiological osmotic conditions. In addition, osmolality identifies the soluble content of a solution. In one embodiment of the invention, the osmolality of the formulation of the invention is less than or equal to about 506 mmol / Kg or about 250 to about 506 mmol / Kg, such as about 250, 260, 270, 280, 290,
[0182] 299, 300, 310, 314, 315, 316, 324, 343, 346, 349, 369, 384, 403, 426, 430 or 506 mmol / Kg. In one embodiment of the invention, the osmolality is less than about 250 mmol / Kg.
[0183] Purity and stability of the preparation
[0184] The preparations containing high concentrations of VEGF receptor fusion proteins described herein are stable during manufacture and storage. The term "stable" herein refers to preparations containing VEGF receptor proteins that maintain chemical and physical stability during manufacture and storage of the preparations, for example, they maintain integrity and have minimal degradation, denaturation or unfolding. The stability of VEGF receptor proteins can be determined at different temperatures and different time periods using analytical techniques available in the art. In particular, various bioassays (e.g., for determining the VEGF receptor fusion proteins herein) can be used. 165 The VEGF receptor chemical stability (potency) was determined by BAF / 3VEGFR1 / EPOR cell line combined with VEGF receptor fusion protein (B ...
[0185] As used herein, reference to a "high molecular weight" (HMW) species of a formulation containing a given VEGF Trap (e.g., aflibercept) refers to any polypeptide or polypeptide complex species in the formulation that elutes from a size exclusion chromatography column (e.g., SE-UPLC) prior to (e.g., having a higher molecular weight than) the VEGF Trap polypeptide and / or its homodimer. The percentage of a HMW species refers to the percentage of this species relative to the total amount of polypeptide in the formulation, e.g., as analyzed by SE-UPLC.
[0186] In one embodiment of the invention, as discussed more fully in the examples below, formulations that are stable for periods of up to 12 months, up to 24 months, and / or up to 36 months when stored at about 2°C to about 8°C exhibit significant VEGF receptor fusion protein potency and physical stability.
[0187] In an embodiment of the present invention, the formulation of the present invention is the following formulation:
[0188] After about 28 days at about 37°C, the high molecular weight species have approximately 3%, 5%, 10%, 11%,
[0189] 12%, 13%, 14%, 15%, 16%, 17%, 18%, 20%, 30%, 35% or 37% (or
[0190] 10-15% or 15-20% or 10-20%) (e.g., as measured by SE-UPLC or SEC)
[0191] After about 28 days at about 37°C, the major species has about 5%, 6%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21% or 22% (or
[0192] 5-20% or 5-10% or 10-15% or 15-20%) reduction (e.g., by SE-UPLC or SEC
[0193] Measurement)
[0194] After about 28 days at about 37°C, about 80%, 81%, 82%, 83%, 84%, 85%,
[0195] 86% or 87% (or about 80-85%) or more of the protein as the major species (e.g., by SE-
[0196] UPLC or SEC measurement)
[0197] After about 28 days at about 37°C, the low molecular weight species increased by about 1 or 1.5 or 2% (or 1-
[0198] 2%) (e.g., measured by SE-UPLC or SEC)
[0199] After about one month at about 37°C, the high molecular weight species increased by about 16%; and / or the main species decreased by about 17% and / or the low molecular weight species increased by about 0.5% or <1%; and / or after about two months at about 5°C, the main species decreased by about 1% and / or the high molecular weight species increased by about 1%, and / or
[0200] or no significant or detectable amounts of low molecular weight (LMW) species; and / or having about 97% of a major species (e.g., as measured by SE-UPLC or SEC) after about 2 months at about 5°C
[0201] After about 12 months at about 2-8°C, the high molecular weight species increased by about 3-3.5% (e.g., by
[0202] SE-UPLC or SEC measurement)
[0203] Less than about 1% or 1%, 2%, 3% or 4% (e.g., 1-4% or 3-4%) reduction in the major species after about 12 months at about 2-8°C (as measured by SE-UPLC or SEC)
[0204] Having about 94% or 95% or more of the protein as the major species (e.g., as measured by SE-UPLC or SEC) after about 12 months at about 2-8°C
[0205] After about 3 months at about 2-8°C, the high molecular weight species increased by about 1% or 2% (e.g., as measured by SE-UPLC or SEC)
[0206] After about 6 months at about 2-8°C, the high molecular weight species increased by about <1%, 1%, or 2% (e.g.,
[0207] Measured by SE-UPLC or SEC)
[0208] At about 5°C for about 5 1 After 2 or 6 months, there are about 2.5, 3.0, or 3.5 (or about 2.5-3.5%) total high molecular weight species (e.g., as measured by SE-UPLC or SEC).
[0209] After about 6 months at about 2-8°C, the major species is reduced by less than about 1% or 1% or 2% (e.g.,
[0210] 0.5-2% or 1-2%) (as measured by SE-UPLC or SEC)
[0211] Having about 96% or 97% or 98% (or 96-98%) or more of the protein as the major species (e.g., as measured by SE-UPLC or SEC) after about 6 months at about 2-8°C
[0212] less than about 5 or 6 or 7% (e.g., about 1.5, 2, 3, 4 or 5%) increase in high molecular weight species (or 1.5-5% or 1.5-2.5%) after about 24 or 36 months at about 2-8°C; and / or having about 3.0, 3.25, 3.5, 4.0, 4.5 or 5% total high molecular weight species; and / or a decrease in major species of about 2% or 3% (or 2-3%); and / or a total amount of major species of about 95% or 96% or more
[0213] (or 95-96%) (e.g., measured by SE-UPLC or SEC)
[0214] After about 1 month at about 37°C, about 97, 98, 99, or 100% (or 97-100%) of the aflibercept in the formulation can be recovered by RP-HPLC
[0215] Having less than about 1.5%, 2%, 2.5%, 3.0% or 3.5% high molecular weight species immediately after production and purification (e.g., as measured by SE-UPLC or SEC)
[0216] Having at least about 70% or 75% (e.g., 70-75%) of aflibercept as the major species / peak (e.g., as measured by capillary isoelectric focusing (cIEF) or imaged capillary isoelectric focusing (non-acidic and non-basic species)) after about 6 months at about 37°C
[0217] An increase in acidic species of about 1 or 2% (or 1-2%) after about 36 months at about 2-8°C (e.g., as measured by capillary isoelectric focusing (cIEF) or imaged capillary isoelectric focusing)
[0218] A decrease of about 1% or less in the major species / peak after about 36 months at about 2-8°C (e.g., as measured by capillary isoelectric focusing (cIEF) or imaged capillary isoelectric focusing)
[0219] - After about 36 months at about 2-8°C, the major species / main peak is about 78-79% (e.g., as measured by capillary isoelectric focusing (cIEF) or imaged capillary isoelectric focusing)
[0220] and / or
[0221] EYLEA did not cause any adverse reactions when administered intravitreally to mammals (e.g., humans or rabbits or mice) (e.g., those with vascularized eye diseases such as wet AMD).
[0222] Clinically distinct adverse events were observed with EYLEA administered intravitreally at 0.5 or 2.0 mg;
[0223] or does not cause clinically apparent inflammation in the eye, prolonged elevation of intraocular pressure (IOP), prolonged increase or decrease in blood pressure, and / or retinal detachment.
[0224] Furthermore, in embodiments of the invention, high concentrations of VEGF receptor fusion proteins are stable because they form little or no acidic charge variants during manufacturing and storage, e.g., little or no charge variants as tested by, e.g., imaged capillary isoelectric focusing.
[0225] In an embodiment of the invention, the formulations of the invention exhibit less than or equal to about 8% low molecular weight (LMW) species.
[0226] In embodiments of the invention, the formulations of the invention have less than about 0.2, 0.4 or 0.5 EU (endotoxin units) / ml of endotoxin;
[0227] In embodiments of the invention, the formulations of the invention are substantially free of particulate matter or particulate matter having a size of about 1, 2, 5, 10, 25 or 50 microns (or larger).
[0228] In an embodiment of the invention, when the preparation of the invention is analyzed by non-reducing CE-SDS (SDS capillary gel electrophoresis), at least 97% of the total peak area is the main peak.
[0229] In embodiments of the invention, when the formulations of the invention are analyzed by size exclusion UPLC (SE-UPLC), at least 93, 94 or 95% of the total peak area is the main peak and less than or equal to 3.5, 4, 5 or 6% is aggregates.
[0230] In an embodiment of the invention, the formulation of the invention is at about 2°C, 3°C, 4°C, 5°C, 6°C, 7°C or 8°C, 2-8°C (e.g., an average temperature of 5°C), 23°C, 25°C, 30°C or 37°C.
[0231] Illustrative preparations
[0232] Illustrative high concentration VEGF receptor fusion protein formulations include the following:
[0233] Formulation A: 80 mg / ml Aflibercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0234] Formulation B: 80 mg / ml Aflibercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0235] Formulation C: 80 mg / ml Aflibercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0236] Formulation D: 80 mg / ml Aflibercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 6.2.
[0237] Formulation E: 80 mg / ml aflibercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0238] Formulation F: 80 mg / ml Aflibercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0239] Formulation G: 80 mg / ml Aflibercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0240] Formulation H: 80 mg / ml Aflibercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0241] Formulation I: 80 mg / ml Aflibercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0242] Formulation J: 80 mg / ml Aflibercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0243] Formulation K: 80 mg / ml Aflibercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0244] Formulation L: 80 mg / ml Aflibercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0245] Formulation M: 150 mg / ml Aflibercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0246] Formulation N: 150 mg / ml Aflibercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0247] Formulation O: 150 mg / ml Aflibercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0248] Formulation P: 150 mg / ml Aflibercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 6.2.
[0249] Formulation Q: 150 mg / ml Aflibercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0250] Formulation R: 150 mg / ml Aflibercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0251] Formulation S: 150 mg / ml Aflibercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0252] Formulation T: 150 mg / ml Aflibercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2 (eg, 6.2), and optionally, specifically excluding viscosity reducing agents.
[0253] Formulation U: 150 mg / ml Aflibercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0254] Formulation V: 150 mg / ml Aflibercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0255] Formulation W: 150 mg / ml Aflibercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0256] Formulation X: 150 mg / ml Aflibercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0257] Formulation Y: 80 mg / ml Conbercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0258] Formulation Z: 80 mg / ml Conbercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0259] Formulation AA: 80 mg / ml Conbercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0260] Formulation BB: 80 mg / ml Conbercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 6.2.
[0261] Formulation CC: 80 mg / ml Conbercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0262] Formulation DD: 80 mg / ml Conbercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0263] Formulation EE: 80 mg / ml Conbercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0264] Formulation FF: 80 mg / ml Conbercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0265] Formulation GG: 80 mg / ml Conbercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0266] Formulation HH: 80 mg / ml Conbercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0267] Formulation II: 80 mg / ml Conbercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0268] Formulation JJ: 80 mg / ml Conbercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0269] Formulation KK: 150 mg / ml Conbercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0270] Formulation LL: 150 mg / ml Conbercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0271] Formulation MM: 150 mg / ml Conbercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0272] Formulation NN: 150 mg / ml Conbercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 6.2.
[0273] Formulation OO: 150 mg / ml Conbercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0274] Formulation PP: 150 mg / ml Conbercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2.
[0275] Formulation QQ: 150 mg / ml Conbercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0276] Formulation RR: 150 mg / ml Conbercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0277] Formulation SS: 150 mg / ml Conbercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0278] Formulation TT: 150 mg / ml Conbercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0279] Formulation UU: 150 mg / ml Conbercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0280] Formulation VV: 150 mg / ml Conbercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2, and optionally, specifically excluding viscosity reducing agents.
[0281] Formulation WW: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM taurine, pH 5.8.
[0282] Formulation XX: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20 mM histidine-based buffer, 4% (w / v) proline, 0.03% (w / v) polysorbate 20, and 50 mM arginine hydrochloride, pH 5.8.
[0283] Formulation YY: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20 mM histidine-based buffer, 2.5% (w / v) sucrose, 2.0% (w / v) proline, 0.03% (w / v) polysorbate 20, and 50 mM taurine, pH 5.8.
[0284] Formulation ZZ: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 10 mM histidine-based buffer, 2.5% (w / v) sucrose, 2.0% (w / v) proline, 0.03% (w / v) polysorbate 20, and 50 mM arginine hydrochloride, pH 5.8.
[0285] Formulation AAA: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM PSA, pH 5.8.
[0286] Formulation BBB: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20 mM histidine-based buffer, 2.5% (w / v) sucrose, 2.0% (w / v) proline, 0.03% (w / v) polysorbate 20, and 50 mM PSA, pH 5.8.
[0287] Formulation CCC: 80, 100, 120 or 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM arginine hydrochloride, pH 5.8.
[0288] Formulation DDD: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 10 mM histidine-based buffer, 4% (w / v) proline, 0.03% (w / v) polysorbate 20, and 50 mM PSA, pH 5.8.
[0289] Formulation EEE: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20 mM histidine-based buffer, 5% (w / v) sucrose and 0.03% (w / v) polysorbate 20, and optionally without a heat stabilizer, pH 5.8.
[0290] Formulation FFF: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 10 mM sodium phosphate, 5% (w / v) sucrose, and 0.03% polysorbate 20, pH 6.2.
[0291] Formulation GGG: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium sulfate
[0292] Formulation HHH: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium thiocyanate
[0293] Formulation III: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 40 mM sodium citrate
[0294] Formulation JJJ: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose, 0.03% polysorbate 20; 50 mM glycine
[0295] Formulation KKK: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose, 0.03% polysorbate 20; 50 mM sodium chloride
[0296] Formulation LLL: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM lysine
[0297] Formulation MMM: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate
[0298] Formulation NNN: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate
[0299] Formulation OOO: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium citrate; 50 mM arginine hydrochloride
[0300] Formulation PPP: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM glycine; 50 mM arginine hydrochloride
[0301] Formulation QQQ: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate; 50 mM arginine hydrochloride
[0302] Formulation RRR: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate; 50 mM arginine hydrochloride
[0303] Formulation SSS: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 10 mM L-arginine hydrochloride
[0304] Formulation TTT: 140 mg / ml VEGF receptor fusion protein (e.g., Aflibercept); 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 100 mM L-arginine hydrochloride
[0305] Formulation UUU: 30 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
[0306] Formulation VVV: 30 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
[0307] Formulation WWW: 60 mg / ml VEGF receptor fusion protein (e.g., Aflibercept), 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
[0308] Formulation XXX: 60 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
[0309] Formulation YYY: 120 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
[0310] Formulation ZZZ: 120 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2
[0311] Formulation AAAA: 120 mg / ml VEGF receptor fusion protein (e.g., Aflibercept), 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, 50 mM NaCl, pH 6.2
[0312] Formulation BBBB: 120 mg / ml VEGF receptor fusion protein (e.g., Aflibercept), 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, 50 mM NaCl, pH 6.2
[0313] Formulation CCCC: 140 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 10 mM sodium phosphate, 5% sucrose, 40 mM sodium chloride, 0.03% PS20, pH 6.2
[0314] Formulation DDDD: 80 mg / ml VEGF receptor fusion protein (eg, Aflibercept), 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM L-arginine monohydrochloride, pH 5.8.
[0315] Formulation EEEE: 120.0 mg / ml VEGF receptor fusion protein (e.g., Aflibercept) (e.g. + 12 mg / ml), 20 mM histidine-based buffer (e.g. + 2 mM), 5% (w / v) sucrose (e.g. + 0.5%), 0.03% (w / v) polysorbate 20 (e.g. 0.02-0.04%) and 50 mM L-arginine monohydrochloride (e.g. + 5 mM), pH 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
[0316] Formulation FFFF: 113.3 mg / ml VEGF receptor fusion protein (e.g., Aflibercept) (e.g., 102-125 mg / ml), 20 mM histidine-based buffer (e.g., + 2 mM), 5% (w / v) sucrose (e.g. + 0.5%), 0.03% (w / v) polysorbate 20 (e.g. 0.02-0.04%) and 50 mM L-arginine monohydrochloride (e.g. + 5 mM), pH 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
[0317] Formulation GGGG: 114.3 mg / ml VEGF receptor fusion protein (e.g., Aflibercept) (e.g., 103-126 mg / ml), 10 mM histidine-based buffer (e.g., +1 mM), 5% (w / v) sucrose (e.g.
[0318] + 0.5%), 0.03% (w / v) polysorbate 20 (e.g. 0.02-0.04%) and 50 mM L-arginine monohydrochloride (e.g. + 5 mM), pH 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
[0319] Formulation HHHH: 100.0 mg / ml VEGF receptor fusion protein (e.g., Aflibercept) (e.g. + 10 mg / ml), 20 mM histidine-based buffer (e.g. + 2 mM), 5% (w / v) sucrose (e.g. + 0.5%), 0.03% (w / v) polysorbate 20 (e.g. 0.02-0.04%) and 50 mM L-arginine monohydrochloride (e.g. + 5 mM), pH 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
[0320] Formulation IIII: 133.3 mg / ml VEGF receptor fusion protein (eg, Aflibercept) (eg, + 13 mg / ml), 20 mM histidine-based buffer (e.g. + 2 mM), 5% (w / v) sucrose (e.g. + 0.5%), 0.03% (w / v) polysorbate 20 (e.g. 0.02-0.04%) and 50 mM L-arginine monohydrochloride (e.g. + 5 mM), pH 5.8 (e.g., 5.6-6.0 or 5.5-6.1).
[0321] Formulation JJJJ: 150 mg / ml Aflibercept (e.g., Aflibercept) (e.g. + 15 mg / ml), 10 mM sodium phosphate, 8% (W / V) sucrose (e.g. + 0.8%), 0.03% (w / v) polysorbate 20 (e.g., 0.02-0.04%), and 50 mM L-arginine hydrochloride, pH 6.2 (e.g., 6.0-6.4 or 5.9-6.5).
[0322] Formulation KKKK: 114.3 mg / ml VEGF receptor fusion protein (e.g., Aflibercept) (e.g. + 14 mg / ml), 20 mM histidine-based buffer (e.g. + 2 mM), 5% (w / v) sucrose (e.g. +0.5%), 0.03% (w / v) polysorbate 20 (e.g. 0.02-0.04%) and 50 mM L-arginine monohydrochloride (e.g. + 5 mM), pH 5.8 (e.g., 5.6-6.0 or 5.5-6.1);
[0323] or any formulation described herein.
[0324] In embodiments of the invention, the concentrations of any formulation composition (e.g., all compositions) listed above or discussed herein (e.g., any of formulations A-KKKK) are 1 / 2 of the specifically mentioned concentrations. + About 3%, 5% or about 10%.
[0325] Manufacturing method
[0326] Embodiments herein include methods of making a pharmaceutical formulation of the invention (e.g., any of formulations A-KKKK described herein) comprising a VEGF receptor fusion protein, the method comprising combining the components of the formulation into a single composition, and optionally introducing the formulation into a container or device (e.g., a vial) or a delivery device (e.g., a prefilled syringe). The formulation, vial, or device that is the product of this method is part of the present invention.
[0327] In an embodiment of the invention, a method for preparing a pharmaceutical formulation of the invention containing a VEGF receptor fusion protein (e.g., any of formulations A-KKKK described herein) comprises the steps of: culturing a host cell (e.g., Chinese hamster ovary cell) containing one or more polynucleotides encoding a VEGF receptor fusion protein (e.g., aflibercept) in a culture medium and under conditions that express the protein; and purifying the protein from the host cell and / or culture medium, and combining a portion of the protein with an excipient of a pharmaceutical formulation described herein. Again, the formulation, vial, or device that is the product of this method is part of the invention.
[0328] In an embodiment of the present invention, the amount and type of VEGF receptor fusion protein required for its high concentration and its final use in the preparation is determined. The same determination is made regarding the amount and type of buffer, the amount and type of surfactant, the amount and type of thermal stabilizer, and the inclusion or specific exclusion of viscosity reducers. These components are combined and mixed to ensure that the pH of the preparation is at a desired value, for example, between about 5.0 and about 6.8 (e.g., 5.8), and / or the viscosity is at a desired value, for example, about 6.0, 7.3, 11.5, or 12.0 cP at 20°C. In an embodiment of the present invention, a preparation containing a high concentration of VEGF receptor fusion protein can be sterilized and stored under stable conditions, for example, at 2°C to 8°C (e.g., 5°C) for up to 24 or 36 months.
[0329] See, e.g., Hardman et al., (2001), Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY; Gennaro, (2000), Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, NY; Avis et al. (eds.), (1993), Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, New York; Lieberman et al. (eds.), (1990), Pharmaceutical Dosage Forms: Tablets. Lieberman et al. (eds.), (1990), Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker & Co., New York;
[0330] Weiner and Kotkoskie, (2000), Excipient Toxicity and Safety, Marcel Dekker & Co., New York.
[0331] Angiogenic eye diseases and cancer
[0332] The pharmaceutical formulations of the invention comprising a VEGF receptor fusion protein (e.g., any one of pharmaceutical formulations A-KKKK) can be used to treat or prevent any angiogenic eye disease by administering a therapeutically effective amount of the VEGF receptor fusion protein in the formulation of the invention to a subject in need thereof, such as by intravitreal injection. Angiogenic eye disease herein refers to any eye disease caused by or associated with the growth or proliferation of blood vessels and / or by vascular leakage. Non-limiting examples of angiogenic eye diseases that can be treated or prevented using the formulations and methods herein include:
[0333] Age-related macular degeneration (wet),
[0334] Macular edema,
[0335] Macular edema after retinal vein occlusion,
[0336] Retinal vein occlusion (RVO),
[0337] Central retinal vein occlusion (CRVO),
[0338] Branch retinal vein occlusion (BRVO),
[0339] Diabetic macular edema (DME),
[0340] Choroidal neovascularization (CNV),
[0341] Iris neovascularization,
[0342] Neovascular glaucoma,
[0343] Postoperative fibrosis in glaucoma,
[0344] Proliferative vitreoretinopathy (PVR),
[0345] · Neovascularization of the optic nerve head,
[0346] Corneal neovascularization,
[0347] · Retinal neovascularization,
[0348] ·Vitreous neovascularization,
[0349] · Corneal pannus,
[0350] · Pterygium,
[0351] Vascular retinopathy,
[0352] Diabetic retinopathy (e.g., non-proliferative diabetic retinopathy (e.g., characterized by a diabetic retinopathy severity scale (DRSS) of about 47 or 53) or proliferative diabetic retinopathy; e.g., in a subject without DME) and
[0353] • Diabetic retinopathy in patients with diabetic macular edema (DME).
[0354] Pharmaceutical formulations of the invention comprising VEGF receptor fusion proteins (e.g., any of pharmaceutical formulations A-KKKK) can be used to treat or prevent any cancer by administering a therapeutically effective amount of a VEGF receptor fusion protein in a formulation of the invention to a subject in need thereof, e.g., by intramuscular, intratumoral, subcutaneous, or intravenous injection. Cancers include those cancers whose growth, proliferation, survival, and / or metastasis are dependent to some extent on angiogenesis. In embodiments of the invention, the cancer is colorectal cancer, lung cancer, skin cancer, breast cancer, brain cancer, stomach cancer, kidney cancer, prostate cancer, liver cancer, or pancreatic cancer.
[0355] Thus, the present invention provides a method for treating or preventing angiogenic eye diseases in a subject in need thereof, the method comprising administering a therapeutically effective amount of a VEGF receptor fusion protein (e.g., aflibercept) intraocularly (e.g., about 4, 6 or 8.0, 8.1, 8.4 or 8.5 mg), e.g., in a pharmaceutical formulation according to the present invention, e.g., into the vitreous of an eye of the subject. In embodiments of the present invention, the VEGF receptor fusion protein is administered to both eyes. In embodiments of the present invention, a therapeutically effective dose of the VEGF receptor fusion protein is administered about every 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, or 24 weeks. In an embodiment of the present invention, the method of treating or preventing is performed in the absence of a significant increase in blood pressure (systolic and / or diastolic pressure) and / or the absence of development of hypertension (e.g., Grade 1, Grade 2, or Grade 3) and / or abnormally high intraocular pressure in the subject. In an embodiment of the present invention, the method comprises the following steps: after the administration, monitoring the subject for a significant increase in blood pressure (systolic and / or diastolic pressure) and / or the development of hypertension (e.g., Grade 1, Grade 2, or Grade 3) and / or abnormally high intraocular pressure.
[0356] Mode of administration
[0357] The pharmaceutical preparation of the present invention comprising VEGF receptor fusion protein can be administered according to known medically approved delivery systems. In embodiments herein, these delivery systems can include administration of the preparation to the patient by eye, intraocular, intrachoroidal, intravitreal or subconjunctival injection. Alternatively, the pharmaceutical preparation of the present invention can also be administered to the patient by topical routes such as eye drops, eye gels, eye ointments, etc. Other possible delivery routes of the preparation herein include intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural and oral.
[0358] In an embodiment of the invention, intravitreal injection of a pharmaceutical formulation of the invention comprises the steps of piercing the eye with a syringe and needle (e.g., a 30-gauge injection needle) containing the formulation and injecting the formulation (e.g., less than or equal to about 100 microliters; about 40, 50, 55, 56, 57, 57.1, 58, 60, 70, or 75 microliters) into the vitreous of the eye (e.g., having a sufficient volume to deliver a therapeutically effective amount of a VEGF receptor fusion protein, e.g., about 4, 5, 6, 7, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, or 8.9, 9, 10, 12, 14, 16, 18, or 20 mg of a VEGF receptor fusion protein). Optionally, the method includes a step of applying a local anesthetic (e.g., procaine, lidocaine, or tetracaine), an antibiotic (e.g., a fluoroquinolone), an antiseptic (e.g., povidone-iodine), and / or a pupil dilator to the eye to be injected. In an embodiment of the present invention, a sterile area around the eye to be injected is established prior to injection. In an embodiment of the present invention, after intravitreal injection, the subject's intraocular pressure and / or blood pressure are monitored for an increase. In an embodiment of the present invention, the other eye is also injected by the same process.
[0359] Dosage of VEGF receptor fusion protein
[0360] Each dose of high concentration VEGF receptor fusion protein administered to a subject during the course of treatment can contain the same or substantially the same amount of fusion protein. Alternatively, the amount of any one dose can be different or variable during the course of treatment.
[0361] An effective or therapeutically effective amount of a VEGF receptor fusion protein for treating or preventing cancer (e.g., mediated at least in part by angiogenesis) or angiogenic eye disease refers to an amount of a VEGF receptor fusion protein sufficient to cause regression, stabilization or elimination of the cancer or angiogenic eye disease, such as by regression, stabilization or elimination of one or more symptoms or signs of the cancer or angiogenic eye disease to any clinically measurable extent (e.g., in the case of angiogenic eye disease), by reducing or maintaining the diabetic retinopathy severity score (DRSS), by improving or maintaining visual acuity (e.g., best corrected visual acuity, e.g., as measured by increasing ETDRS letters), increasing or maintaining visual fields and / or reducing or maintaining central retinal thickness, and in the case of cancer, halting or reversing the growth, survival and / or metastasis of cancer cells in a subject. In an embodiment of the invention, an effective or therapeutically effective amount of a VEGF receptor fusion protein for treating or preventing angiogenic eye diseases is about 0.5 mg to about 10 mg or 0.5 mg to about 20 mg per dose, including: about 0.5 mg or more; or about 2 mg or more, such as about 2.1 mg; 2.2 mg; 2.3 mg; 2.4 mg; 2.5 mg; 2.6 mg; 2.7 mg; 2.8 mg; 2.9 mg; 3.0 mg; 3.1 mg; 3.2 mg; 3.3 mg; 3.4 mg;
[0362] 3.5mg; 3.6mg; 3.7mg; 3.8mg; 3.9mg; 4.0mg; 4.1mg; 4.2mg; 4.3mg;
[0363] 4.4mg; 4.5mg; 4.6mg; 4.7mg; 4.8mg; 4.9mg; 5.0mg; 5.1mg; 5.2mg;
[0364] 5.3mg; 5.4mg; 5.5mg; 5.6mg; 5.7mg; 5.8mg; 5.9mg; 6.0mg; 6.1mg;
[0365] 6.2mg; 6.3mg; 6.4mg; 6.5mg; 6.6mg; 6.7mg; 6.8mg; 6.9mg; 7.0mg;
[0366] 7.1mg; 7.2mg; 7.3mg; 7.4mg; 7.5mg; 7.6mg; 7.7mg; 7.8mg; 7.9mg;
[0367] 8.0mg; 8.1mg; 8.2mg; 8.3mg; 8.4mg; 8.5mg; 8.6mg; 8.7mg; 8.8mg;
[0368] 8.9mg; 9mg; 9.1mg; 9.2mg; 9.3mg; 9.4mg; 9.5mg; 9.6mg; 9.7mg;
[0369] 9.8mg; 9.9mg, 10.0mg, 10.1mg; 10.2mg; 10.3mg; 10.4mg; 10.5mg; 10.6mg; 10.7mg; 10.8mg; 10.9mg; 11mg; 11.1mg; 11.2mg; 11.3mg; 11.4mg; 11.5mg; 11.6mg; 11.7mg; 11.8mg; 11.9mg; 12mg; 12.1mg; 12.2mg; 12.3mg ;12.4mg;12.5mg;12.6mg;12.7mg;12.8mg;12.9mg;13mg;13.1mg;13.2mg;13.3mg;13.4mg;13.5mg;13.6 mg; 13.7mg; 13.8mg; 13.9mg; 14mg; 14.1mg; 14.2mg; 14.3mg; 14.4mg; 14.5mg; 14.6mg; 14.7mg; 14.8mg; 14. 9mg; 15mg; 15.1mg; 15.2mg; 15.3mg; 15.4mg; 15.5mg; 15.6mg; 15.7mg; 15.8mg; 15.9mg; 16mg; 16.1mg; 16. 2mg; 16.3mg; 16.4mg; 16.5mg; 16.6mg; 16.7mg; 16.8mg; 16.9mg; 17mg; 17.1mg; 17.2mg; 17.3mg; 17.4mg; 17 .5mg; 17.6mg; 17.7mg; 17.8mg; 17.9mg; 18mg; 18.1mg; 18.2mg; 18.3mg; 18.4mg; 18.5mg; 18.6mg; 18.7mg; 18.8mg; 18.9mg; 19mg; 19.1mg; 19.2mg; 19.3mg; 19.4mg; 19.5mg; 19.6mg; 19.7mg; 19.8mg; 19.9mg; or 20mg. In an embodiment of the present invention, the effective amount or therapeutically effective amount of VEGF receptor fusion protein for treating or preventing cancer is about 4mg / kg (e.g., intravenous injection). This dose can be administered, for example, once every 2 weeks.
[0370] In embodiments of the invention, the VEGF receptor fusion protein is administered in a volume sufficient to deliver, for example, a desired dose of the fusion protein as described above. In embodiments of the invention, the volume delivered (e.g., for example, by intravitreal injection for the treatment or prevention of angiogenic eye disease) is less than or equal to about 100 microliters (e.g., about any of the following volumes: 25 microliters; 26 microliters; 27 microliters; 28 microliters; 29 microliters; 30 microliters; 31 microliters; 32 microliters; 33 microliters; 34 microliters; 35 microliters; 36 microliters; 37 microliters;
[0371] 38μl; 39μl; 40μl; 41μl; 42μl; 43μl; 44μl; 45μl;
[0372] 46 μl; 47 μl; 48 μl; 49 μl; 50 μl; 51 μl; 52 μl; 53 μl;
[0373] 54 μl; 55 μl; 56 μl; 57 μl; 58 μl; 59 μl; 60 μl; 61 μl;
[0374] 62 μl; 63 μl; 64 μl; 65 μl; 66 μl; 67 μl; 68 μl; 69 μl;
[0375] 70 microliters; 71 microliters; 72 microliters; 73 microliters; 74 microliters; 75 microliters; 76 microliters; 77 microliters;
[0376] 78 μl; 79 μl; 80 μl; 81 μl; 82 μl; 83 μl; 84 μl; 85 μl;
[0377] 86 microliters; 87 microliters; 88 microliters; 89 microliters; 90 microliters; 91 microliters; 92 microliters; 93 microliters;
[0378] 94 μl; 95 μl; 96 μl; 97 μl; 98 μl or 99 μl).
[0379] In embodiments of the invention, the formulation is administered (e.g., by, e.g., intravitreal injection for treatment or prevention of angiogenic eye diseases) in a volume of about 60 microliters or less, about 70 microliters or less, or about 75 microliters or less, or about 100 microliters or less. For example, in embodiments of the invention, about 2, 4, 6, 8.0, 8.1, 8.0-8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, or 8.9, 9.0, or 10 mg of VEGF receptor fusion protein is administered in about 50, 60, 70, or 75 microliters.
[0380] The scope of the invention also includes methods of delivering 0.5 or 2 mg of VEGF receptor fusion protein in a pharmaceutical formulation of the invention in a low volume, e.g., less than 50 □ l (e.g., about 1, 5, 10, 17, 17.5, 18, 18.5, 20, 30, 40 or 45 □ l) (e.g., for treating or preventing angiogenic eye diseases, e.g., by intravitreal injection).
[0381] The invention also includes a composition comprising, consisting of, or consisting essentially of a "single dose volume" of a pharmaceutical formulation of the invention, i.e., a volume (e.g., about 50 □ l or 60 □ l, 70 □ l or 75 □ l or any volume containing about 4, 6, 8 or 10 mg of VEGF receptor fusion protein) that contains a single dose of the pharmaceutical formulation of the invention (e.g., aflibercept). As described below, a container (e.g., a vial or injection device) of the formulation that includes a single dose volume, optionally including a small overfill volume, is also part of the invention.
[0382] Containers and injection devices
[0383] According to the high concentration VEGF receptor fusion protein preparations of the embodiments of the present invention (e.g., any of preparations A-KKKK) can be prepackaged or preloaded in various useful containers and injection devices. Therefore, the present invention includes containers and injection devices containing such preparations. In embodiments herein, the container is a vial that can be sterile. In another embodiment herein, the container is a test tube that can be sterile. In embodiments of the present invention, the injection device (which can be sterile) is a syringe (e.g., a prefilled syringe or an automatic syringe). In one embodiment of the present invention, the injection device is an intravitreal implant, such as a refillable intravitreal implant.
[0384] A "prefilled" syringe is a syringe that is filled with a formulation of the invention prior to sale or use by a physician or patient.
[0385] As used herein, "sterile" means free of pathogens or being free of substantially all or all living microorganisms and their spores.
[0386] The syringe used herein includes a barrel, which is made of, for example, glass or a polymer such as a cyclic olefin described in U.S. Patent Publication 2017 / 0232199 (which is incorporated herein for all purposes), a plunger and a needle.
[0387] The container and injection device may be coated with silicone (e.g. silicone oil or baked silicone (e.g. < 40□g or < 100□g)).
[0388] In embodiments of the invention, the container or injection device is substantially metal-free or substantially tungsten-free or low in tungsten.
[0389] In one embodiment of the invention, the syringe comprises one or more dose line graduations and / or a dose metering system.
[0390] Containers according to embodiments herein can hold high concentrations of VEGF receptor fusion protein preparations. In some aspects, containers or injection devices may include labels stating instructions for use. In some cases, containers or injection devices herein may include a package insert with instructions for use as described throughout this specification.
[0391] In other embodiments, a volume (as described above) containing a single dose or multiple doses (e.g., 2 or more than 2) of a high concentration VEGF receptor fusion protein (e.g., a VEGF receptor fusion protein in which the dose is 2 mg, 4 mg, 6 mg, 8 mg, or 10 mg) can be prepackaged into a container or injection device, such as a sterile syringe, for storage until use. In one example, the volume in the container includes a single dose of VEGF receptor fusion protein, optionally also including a small amount of overfill volume. The sterile prefilled syringe can be kept under storage conditions (e.g., 2° C.-8° C.), for example, up to 12 months, 24 months, or 36 months. Overfill refers to an excess volume sufficient to allow withdrawal and / or administration of an appropriate volume. In one embodiment of the invention, the container has a single dose volume or multiple dose volumes and an overfill volume of about 5%-10%.
[0392] The size of the syringe can be, for example, 0.3cc, 0.5cc, or 1cc. The sterile syringe typically includes a needle that can be used for intraocular injections, which is generally about 1 / 2 inch, or 12.5mm to 16mm in length, and can be 29-gauge, 30-gauge, 31-gauge, 32-gauge, or 33-gauge, depending on the preference of the patient and the healthcare professional. Other needle lengths and gauges can be used as long as the needle is effective for intravitreal injections.
[0393] While the present invention has been particularly shown and described with reference to a number of embodiments, those skilled in the art will understand that changes in form and details may be made to the various embodiments disclosed herein without departing from the spirit and scope of the present invention and that the various embodiments disclosed herein are not intended to limit the scope of the claims.
[0394] Other preparations
[0395] The present invention includes the following formulations, which include greater than 40 mg / ml of a VEGF receptor fusion protein (e.g., aflibercept or conbercept) and:
[0396] (a) a buffer comprising a histidine salt (e.g., histidine-HCl or histidine-acetate, e.g., 10 mM to 50 mM) and a pH of 5.7 to 6.2; a sugar (e.g., greater than 6%, but not greater than 10%), such as sucrose, trehalose, mannitol or glucose; and a surfactant selected from polysorbate 20 and polysorbate 80 (e.g., 0% to 0.1%);
[0397] (b) a buffer containing histidine, such as L-histidine / histidine hydrochloride (e.g. 10 mM); a non-ionic surfactant, such as polysorbate 20 (e.g. 0.03%), an inorganic salt, such as NaCl (e.g. 40 mM) and a carbohydrate, such as sucrose (e.g. 5%), for example, at pH 6.0-6.5 (e.g. 6.2 or 6.5);
[0398] (c) citric acid (e.g., 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, or 30 mM), sucrose (e.g., 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%), arginine (e.g., 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, or 50 mM or 100 mM), polysorbate 20 (e.g., 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.10%);
[0399] (d) a buffer such as phosphate, histidine, acetate, succinate, citrate, glutamate and / or lactate (e.g. 5-20 or 5-50 mM); a nonionic surfactant such as a polysorbate (e.g. PS20 or PS80), polyethylene glycol lauryl ether, poloxamer, 4-(1,1,3,3-tetramethylbutyl)phenyl-polyethylene glycol, an alkyl sugar or alkyl glycoside, a tonicifying agent such as a polyol or an amino acid such as sucrose, trehalose, sorbitol, mannitol, glycerol, proline, arginine, methionine, glycine or lysine, wherein the final osmotic pressure of the formulation is about 300 mOsm / kg and wherein the concentration of chloride anions is less than about 10 mM; pH 5.0-6.5; or
[0400] (e) 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20 and 5% sucrose, pH 6.2. DETAILED DESCRIPTION
[0402] Example
[0403] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the present invention. Efforts have been made to ensure the accuracy of the numbers used, but some experimental errors and deviations should be considered. Any formulation listed in these examples is part of the present invention.
[0404] In these examples, when an experiment is conducted at 2-8°C, the temperature target is 5°C, with + 3℃ variation tolerance.
[0405] Example 1 : 80 mg / ml VEGF receptor fusion protein formulations maintained potency, physical stability, and charge over a period of 36 months.
[0406] A series of four different formulations with 80 mg / ml VEGF receptor fusion protein (Aflibercept) were tested for long-term efficacy, physical stability, and formation of charge heteromers. The list of ingredients for each of the four formulations is listed in Table 1-1. The formation of HMW species of VEGF receptor fusion protein during 36 months of storage at 2°C to 8°C for each formulation, as well as the percentage of major species, were evaluated by SE-UPLC. Each formulation containing VEGF receptor fusion protein was also evaluated over the same time course and temperature using imaging capillary isoelectric focusing. Finally, the efficacy of each formulation was tested by bioassay over the same time course and temperature.
[0407] Table 1-1. Preparations containing VEGF receptor fusion protein
[0408]
[0409] Table 1-2. % HMW species
[0410]
[0411] Table 1-3. % Main Peak
[0412]
[0413]
[0414] Table 1-4. % Acidic species
[0415] Preparation B Preparation H Preparation D Formulation G Preparation 1 Preparation 2 Preparation 3 Preparation 4 2-8℃ months 0.0 15.8 15.1 16.0 15.2 12 15.6 15.9 NP 16.0 24.0 16.0 17.1 16.2 16.9 36.0 16.9 17.4 17.2 17.6
[0416] Table 1-5. Main types
[0417]
[0418]
[0419] Data shown in Figure 1A ,1B , 1C and 1D. Figure 1A The percentage of HMW species of VEGF receptor fusion protein formed in each of the four formulations is shown. The rate of formation of HMW species of VEGF TRAP was slightly slower when the formulation was histidine-based compared to sodium phosphate. Figure 1A As shown, the % HMW species after 36 months storage at 2°C to 8°C increased by 2.6% in the sodium phosphate formulations (Formulations 1 and 2) compared to an increase of 1.6% to 1.9% in the histidine buffer (Formulations 3 and 4). Figure 1B The data were confirmed as shown, where SE-UPLC was used to identify the percentage of the major species of VEGF receptor fusion protein present over the same time frame and temperature range. As a point of comparison, the current The VEGF TRAP formulation (40 mg / ml) was tested, which showed that the % HMW species increased by 1.2% after storage at 2°C to 8°C for 36 months (not shown). In addition, the efficacy of each of the four 80 mg / ml VEGF TRAP formulations was tested and compared with The activities were compared (not shown). These data indicate that the formulations herein are able to maintain efficacy in the presence of Comparable VEGF receptor fusion protein stability.
[0420] Reference Figure 1C and 1D The percentage of VEGF TRAP charge variants formed after storage at 2°C to 8°C for 36 months was also tested. Figure 1C showed that the VEGF TRAP in formulations 1-4 showed no meaningful change in the percentage of acidic species over the course of 36 months, Figure 1D The same findings for the percentage of major species over the course of 36 months are shown.The finding that VEGFTRAP retains charge heteromeric species during storage suggests that the quality of VEGF TRAP is maintained and processes such as deamination, N-terminal pyroglutamate formation, isomerization, aggregation, etc., do not occur during storage parameters.
[0421] The data in Example 1 show that Formulations with twice the concentration of VEGF TRAP in the 100 μg / ml buffer maintained physical stability, quality, and potency over the course of 36 months at 2°C to 8°C. In addition, while all four formulations showed similar potency over this period, the histidine-containing formulations resulted in slightly less increase in HMW species formation (a sign of protein degradation), suggesting that histidine may be the buffer of choice in some cases. However, the findings for histidine- and phosphate-based buffers showed excellent stability throughout the study.
[0422] Example 2 : VEGF TRAP stability at 150 mg / ml in sodium phosphate buffer / sucrose formulation.
[0423] The physical stability of 150 mg / ml VEGF Trap (Aflibercept) in two sodium phosphate formulations was tested at 37°C for 28 days. The ingredient list of each of the two formulations is listed in Table 2-1. The formation of HMW species and the percentage of major species were evaluated for each formulation during storage at 37°C for 28 days by SE-UPLC.
[0424] Table 2-1. Preparations containing VEGF receptor fusion protein (Aflibercept) of Example 2
[0425]
[0426] Table 2-2. % HMW Types
[0427]
[0428]
[0429] Table 2-3. % Main Peak
[0430]
[0431] Figure 2A showed that there was no meaningful difference in the % HMW species formed between the two formulations during storage at 37°C for 28 days, which was confirmed by the percentage of the major species determined by SE-UPLC ( Figure 2B There were no changes in appearance, turbidity, or pH for either formulation over the course of 28 days (not shown).
[0432] The results were then compared with the The formulation of and formulation 1 of Example 1 (80 mg / ml VEGF TRAP in sodium phosphate buffer) were compared. The 150 mg / ml VEGFTRAP formulation showed a higher percentage of HMW species formation compared to the 150 mg / ml formulation and a slightly higher percentage of HMW species formation compared to Formulation 1 of Example 1.
[0433] Further testing of formulations containing high concentrations of VEGF TRAP showed that histidine-containing formulations provided better protection for these molecules than sodium phosphate-based formulations. In addition, incorporation of sodium chloride into each of the tested formulations actually resulted in VEGF TRAP instability at 37° C. The data in Example 2 show that even at high concentrations of 150 mg / ml of VEGF receptor fusion protein and fairly high temperature storage, the formulations herein provide excellent protection for physical stability.
[0434] Example 3: Pharmaceutically acceptable formulation viscosity can be achieved for 150 mg / ml VEGFTRAP.
[0435] A number of formulations containing VEGF Trap (Aflibercept) were tested for their viscosity properties. Formulations with 10 mg / ml to 160 mg / ml VEGF Trap were tested in the presence and absence of various viscosity reducing agents.
[0436] Figure 3A Shown there is 155mg / ml VEGF Trap in 10mM sodium phosphate buffer, 5% sucrose and pH6.2 and in combination with no inorganic salts, arginine, lysine, sodium chloride and magnesium chloride formulations show that viscosity has almost no difference. In each case, viscosity is measured in cP at 20 ℃. Observe that the viscosity range is between about 17cP (no inorganic salt) and 15cP (100mM magnesium chloride), with almost no change between using viscosity reducers or having viscosity reducers completely. Figure 3B A similar series of formulations is shown, except that the alkaline buffer is 10 mM histidine and pH 5.8. Here, the lack of any inorganic salts provides a formulation with a viscosity of 11.5 cP and 50 mM lysine for a viscosity of 14 cP. The buffer containing histidine has excellent viscosity, consistent with other low concentration bioinjectables.
[0437] The viscosity of VEGF Trap was tested at concentrations between 10 mg / ml and 160 mg / ml in the absence of arginine at pH 6.2 with 10 mM sodium phosphate, 5% sucrose, and at 50 mM arginine hydrochloride. The inclusion of a viscosity reducing agent resulted in similar viscosities for all VEGF Trap concentrations tested. Figure 3A and 3B As shown, even at higher protein concentrations, the viscosity reducers had little positive effect on formulation viscosity. This was a surprising result because arginine and other viscosity reducers have previously been shown to have beneficial properties on high protein concentration viscosity.
[0438] Table 3-1. Viscosity - Phosphate Preparations (cP at 20°C)
[0439] Buffer composition 10 mM sodium phosphate, 5% sucrose, pH 6.2 No viscosity reducers 17.3 100 mM arginine 16.2 200 mM arginine 15.8 50 mM lysine 16.2 100 mM NaCl 16.5 50 mM MgCl 16.3 100 mM MgCl 15.3
[0440] Table 3-2. Viscosity - Histidine Preparation (cP at 20°C)
[0441] Buffer composition 10 mM histidine, pH 5.8 No viscosity reducers 11.5 100 mM arginine 12.0 200 mM arginine 12.7 50 mM lysine 14.0 200 mM lysine 14.1 50 mM NaCl 13.1 100 mM NaCl 12.1 50 mM MgCl 12.6 100 mM MgCl 11.4
[0442] Example 4: Arginine hydrochloride improves the stability of 150 mg / ml VEGF TRAP in a sodium phosphate buffer / sucrose formulation Qualitative.
[0443] The physical stability of 150 mg / ml VEGF Trap (Aflibercept) in two sodium phosphate formulations was tested at 2-8°C for 12 months. The list of ingredients for each of the two formulations is listed in Table 4-1. Formulation 2 also contained 50 mM arginine hydrochloride. The formation of HMW species and the percentage of major species were evaluated for each formulation during storage at 37°C for 12 months by SE-UPLC.
[0444] Table 4-1. Preparations containing VEGF receptor fusion protein (Aflibercept) of Example 3
[0445]
[0446] Figure 4A The inclusion of 50 mM arginine hydrochloride in the formulation improved the physical stability of VEGF TRAP. Figure 4B This was demonstrated in , where the percentage of the major species of VEGF TRAP remained high in the presence of 50 mM arginine HCl. This data suggests that, in some cases, the addition of arginine HCl can provide a stabilizing effect on stored VEGF TRAP. The size exclusion chromatography data are listed in Tables 4-2 and 4-3.
[0447] Table 4-2. % HMW types
[0448]
[0449]
[0450] Table 4-3. % Main Peak
[0451]
[0452] Example 5: Viscosity 10 mg / ml to 170 mg / ml VEGF TRAP in histidine and phosphate buffer
[0453] Figure 5 Both 10 mM phosphate buffer and 10 mM histidine buffer were shown to have very useful viscosities for a range of VEGF Trap (Aflibercept) concentrations. At higher VEGF Trap concentrations, histidine buffer showed an improvement in viscosity (relative to phosphate). Viscosity was measured at 20°C.
[0454] Example 6: Taurine and propane sulfonic acid provide improved performance for high concentration VEGF Trap (aflibercept) formulations stability.
[0455] Experiments were performed to determine the effects of various formulation combinations on protein stability. Figure 6 Dynamic light scattering plots are shown for formulations with any value from 2 mg / ml protein to 10 mg / ml protein (aflibercept). Formulations containing 70 mM taurine or 70 mM PSA showed reduced self-interaction at higher concentrations. These data suggest that taurine and PSA may be useful inclusions in high concentration protein formulations, as discussed in this case.
[0456] Example 7: Long-term study of the stability of various histidine-containing formulations.
[0457] A total of 9 different aflibercept formulations were tested with different buffer concentrations, thermal stabilizers, and hydrophobic salts. Table 7-1 summarizes the 9 formulations F1-F9.
[0458] Table 7-1. Formulations F1-F9.
[0459]
[0460] VEGFT=VEGF Trap (Aflibercept)
[0461] Fourteen (14) mL of each formulation were mixed in a 15 mL Falcon tube. The formulations were then sterile filtered using a 0.22 μM syringe filter and filled into sterile 2 mL Type 1 glass vials. In a laminar flow hood, eight (8) vials were filled with each formulation at a volume of 0.4 mL.
[0462] SE-UPLC (molecular weight species) was performed on all samples to determine the chemical stability of each formulation.
[0463] Figure 7 The percentage of HMW species over time for each formulation F1-F9 is shown in (see also Table 7-2). Formulations F4 and F7 showed the lowest percentage of HMW species after 4 months at 5°C. The results show that the addition of excipients such as arginine and proline can significantly reduce the rate of %HMW species formation in VEGF Trap formulations.
[0464] Table 7-2. SE-UPLC analysis (2-8°C)
[0465]
[0466]
[0467] Example 8: Stability study of 140 mg / mL VEGF Trap with different arginine concentrations.
[0468] The effect of different concentrations of arginine hydrochloride on the stability of four 140 mg / mL VEGF Trap (Aflibercept) ophthalmic product formulations was studied. Stability assessment was performed under storage conditions of 2-8°C. The drug (DP) was also incubated under stress (37°C) conditions. The four formulations (F1-F4) evaluated in this stability study are described in Table 8-1 below.
[0469] Table 8-1. Formulations F1-F4
[0470]
[0471] About 145 mL of 187 mg / mL VEGF Trap Histidine formulation was thawed. Thirty-six (36) mL of each formulation was mixed, except F3; 39 mL of F3 block was mixed. Each formulation was filter sterilized using a 0.22 □m Durapore PVDF sterilizing filter in a LFH (laminar flow hood) before filling. Clean, depyrogenated 2 mL Type I Schott glass vials, which were plugged with 13 mm serum bottle stoppers (S2-F451 4432 / 50B2-40) were used for stability studies.
[0472] SE-UPLC analysis of the formulations was performed as described above. The measured values of % HMW using SE-UPLC over time in each formulation are listed in Figure 8 (AB). See also Tables 8-2 and 8-3.
[0473] When stored at 5°C, these formulations had a reduced rate of %HMW species formation that was proportional to the concentration of arginine HCl. However, under stress, this effect was reversed. The formulations showed a significant increase in %HMW species at 37°C that was proportional to the concentration of arginine HCl. This property makes it highly unlikely that the beneficial effects of arginine on aflibercept were found in the presence of histidine buffer. Typically, for formulation development in the biotechnology industry, various excipients are first screened for their effects on the drug under stress (e.g., at high temperatures, such as 37°C) for a short period of time. The purpose of this approach is to quickly eliminate excipients that may not perform well under longer periods of no stress (e.g., at lower temperatures, such as 5°C). Despite the effect of arginine on stability at 37°C, it is still considered a useful excipient. Since formulated drug products are typically stored at 4-5°C for several months after production, aflibercept in arginine and histidine buffers would be a very valuable formulation for long-term stable storage of drug products.
[0474] Table 8-2. SE-UPLC analysis (2-8°C)
[0475]
[0476]
[0477] Table 8-3. SE-UPLC analysis (37°C)
[0478]
[0479] Example 9: Stability of VEGFTrap in the presence of counterions from the Hofmeister series and other excipients Qualitative.
[0480] The effects of various counterions and other excipients on the stability of several formulations were determined.
[0481] A. Counterion Screening
[0482] Counterions (e.g., sulfate, thiocyanate, and citrate) were tested in the sodium salt form with a high concentration VEGF Trap (aflibercept) formulation (140 mg / ml). In addition, other amino-added excipients (e.g., glycine and lysine) were also tested.
[0483] Thaw approximately 42 ml of 187 mg / ml VEGF Trap ophthalmic drug. Prepare 50 ml of intermediate formulated drug substance (155.56 mg / ml) with 110% concentration of formulated drug substance of 140 mg / ml and target excipient concentrations (excluding counterions, glycine and lysine).
[0484] The intermediate formulated drug substance was further diluted with 0.5 M excipient stock solution (counter ion, glycine or lysine) to produce the 140 mg / ml formulated drug substance formulations listed in Table 9-1 below. Each final formulation was sterilized in a laminar flow hood using a 0.22 μm PVDF syringe filter and then filled into clean, depyrogenated 2 mL Type I Schott glass bottles with 13 mm serum stoppers S2-F451.
[0485] 4432 / 50 82-40 (ELN Item No. 19700004 Flushing No. 0 000078949) stoppered. Sixty (60) vials contained 0.5 ml of each formulation. Six (6) vials contained 1.5 ml.
[0486] Table 9-1. Preparations used for counterion screening
[0487]
[0488] B. Glutamate and Aspartate Screening
[0489] The stability of high concentration formulations (140 mg / ml) of VEGF Trap (Aflibercept) was tested in the presence of organic counterions in combination with arginine hydrochloride. In addition, the compatibility of two new counterions (glutamic acid and aspartic acid) with high concentration VEGF Trap (with and without arginine hydrochloride) was tested. Table 9-2 below summarizes the formulations tested.
[0490] About 50 ml of 187 mg / ml VEGF Trap drug was thawed. 60 ml of intermediate formulated drug substance (155.56 mg / ml) was prepared, which had 110% of the 140 mg / ml formulated drug substance and the target excipient concentration (excluding counterions, citric acid, glycine, glutamic acid and aspartic acid). The intermediate formulated drug substance was further diluted with 1M excipient stock solution (arginine hydrochloride, sodium citrate, glycine, sodium glutamate and sodium aspartate) to produce the 140 mg / ml formulated drug substance formulations listed in the table below. Each final formulation was sterilized in a laminar flow hood using a 0.22 μm PVDF syringe filter and then filled into clean, depyrogenated, 2 mL Type I Schott glass vials stoppered with 13 mm serum stoppers S2-F4514432 / 50B2-40 (ELN Item No. 19700004 Flush No. 0000078949). Sixty (60) vials were filled with 0.5 ml of each formulation. Six (6) vials were filled with 1.5 ml.
[0491] Table 9-2. Preparations for glutamate and aspartate screening
[0492]
[0493]
[0494] Using RHEOSENSE The viscosity test is performed with a viscometer. Approximately 0.5 mL of undiluted sample is loaded onto a glass syringe. The sample is equilibrated to the desired temperature and then injected into the chip or measuring cell. The viscosity is calculated by measuring the pressure drop from the inlet to the outlet, which is related to the shear stress on the chip wall. The result is expressed in mPas-1 or cp. See Fig. 9 and Table 9-3.
[0495] Osmolality testing is performed using a VAPRO vapor pressure osmometer. Approximately 10 μL of undiluted sample is inoculated into a paper disc. The dew point temperature drop is a function of the vapor pressure of the solution, measured by a sensitive thermocouple and reported as the osmolality of the solution. Results are expressed as mmol / kg or mOsm. See Fig.10 and Table 9-3.
[0496] High molecular weight species were also evaluated by SE-UPLC over time in certain formulations after storage at 37° C. or 5° C. See FIG. 11 (AB) and Tables 9-4 and 9-5.
[0497] Dynamic light scattering experiments were performed using Plate Reader II. Approximately 100 μL of undiluted sample was loaded into a 96-well plate. 35 acquisitions were performed per well at 25°C. Analysis using a regularized autocorrelation function was performed on DYNAMICS v7.1 software. Radius (nm) vs. %Intensity plots and %Mass vs. Radius (nm) plots were generated to derive the average molecular radius and %Polydispersity value (%Pd) for each sample. See Fig.12 .
[0498] Table 9-3. Viscosity and weight gram molecular osmotic concentration of various preparations
[0499]
[0500] Table 9-4. SE-UPLC analysis; % HMW (37°C)
[0501]
[0502]
[0503] Table 9-5. SE-UPLC analysis; % HMW (5°C)
[0504]
[0505] Example 10: Tolerability of IVT-delivered high-dose VEGF trap (140 mg / ml) in normal rabbits.
[0506] Anti-VEGF therapy administered by intravitreal injection is currently the standard of care for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and retinal vascular occlusive disease. However, monthly or bimonthly intravitreal injections impose a huge treatment burden on patients, caregivers, and physicians. More effective and durable therapies are urgently needed in clinical practice. This study aimed to investigate the tolerability of a stably formulated high-dose VEGF Trap (140 mg / ml, equivalent to 14 times the clinical dose) in normal New Zealand white rabbit eyes.
[0507] Two formulations of high-dose VEGF-Trap (Aflibercept) in histidine buffer or phosphate buffer were tested. Three rabbits per group received 7 mg VEGF Trap at 50 mg / L by a single bilateral intravitreal injection of each formulation. Ocular inflammation signs were monitored by slit lamp, optical coherence tomography (OCT) and fundus angiography on the 1st day, 4th day, 1st week after intravitreal administration, and then once a week until 12 weeks. Intraocular pressure was measured with Tonopen before, 10 minutes and 30 minutes after intravitreal injection, and then at each follow-up time point. Animals were euthanized at week 12.
[0508] Give the rabbit's eyes any of the following:
[0509] (1) 140 mg / ml Aflibercept, 20 mM histidine, 5% sucrose, 50 mM arginine HCl, 0.03% PS20, pH 5.8;
[0510] or
[0511] (2) 140 mg / ml Aflibercept, 10 mM sodium phosphate, 5% sucrose, 40 mM sodium chloride, 0.03% PS20, pH 6.2.
[0512] Two of the six eyes in the histidine buffer group had a dark shadow on the vitreous up to 8 weeks after IVT, which was confirmed by slit-lamp examination to be a localized cataract due to surgery-related posterior lens damage. One of the six eyes in the phosphate buffer group had a dark shadow on the vitreous up to 8 weeks after IVT, which was confirmed by slit-lamp examination to be a localized cataract due to surgery-related posterior lens damage.
[0513] The high-dose VEGF Trap (140 mg / ml) formulation tested was well tolerated in normal New Zealand white rabbit eyes within 12 weeks after a single intravitreal administration. After a single intravitreal injection of 7 mg VEGF Trap, no abnormalities or signs of inflammation were observed in the fundus. The vitreous was clear and the retinal vascular morphology was normal. No retinal detachment, hemorrhage, or changes in the optic nerve head were observed. There was no change in intraocular pressure compared to baseline. Baseline fluorescein angiography (FA) and OCT images of rabbit eyes are shown in Figure 13 (AD). Figures 14, 15, 16, and 17 show FA and OCT images of rabbit eyes over time in each treatment group over 8 weeks. Data from the left eye (OS) or right eye (OD) of rabbits 326 and 329 are shown.
[0514] Example 11: Evaluation of the stability of formulation UUU-BBBB
[0515] This study examined the stability of 60 mg / ml and 120 mg / ml VEGF Trap (Aflibercept) in 10 mM phosphate, 10% or 20% sucrose (Suc.), 0 or 50 mM NaCl, 0.03% polysorbate 20, pH 6.2 when incubated at 37°C for up to 6 months. Table 11-1 below lists the formulations used for this stability study.
[0516] Table 11-1. Formulation UUU-BBBB
[0517]
[0518] Base formulation: 10 mM phosphate, 0.03% polysorbate 20, pH 6.2 VEGF Trap = Aflibercept
[0519] Prior to dispensing, formulations were filter sterilized using PVDF 0.2 μm filters in a laminar flow hood.
[0520] The vials containing each formulation were stored at 37°C for 1 month.
[0521] Table 11-2. Reverse phase high performance liquid chromatography (RP-HPLC) results
[0522]
[0523]
[0524] VGFT = VEGF Trap, Aflibercept
[0525] Table 11-3. Size Exclusion Ultra Performance Liquid Chromatography (SE-UPLC) Results
[0526]
[0527] VGFT = VEGF Trap, Aflibercept
[0528] All preparations were essentially free of particles by visual inspection and optical density measurement. After 1 month at 37°C, there was no significant loss of protein recovered by RP-HPLC (Table 11-2), and this trend continued for 6 months.
[0529] The main degradation pathway of VEGF Trap is aggregation under these conditions (Figure 18 (AB); Table 11-3). The stability of VEGF Trap depends on the protein and sucrose concentrations. Formulations with lower VEGF Trap concentrations and higher sucrose are more stable. Maintaining the same protein:sucrose ratio does not result in the same degradation rate. For example, F1 and F4 have the same protein:sucrose ratio of 3:1, but due to the higher protein concentration of F4, it is less stable than F1. Similar trends were observed at 6 months.
[0530] Example 12 : Repeated-dose intravitreal toxicology study in monkeys with different aflibercept formulations.
[0531] In this example, the safety of various formulations in cynomolgus monkeys was evaluated. For Groups 1-3, a total of 7 intravitreal doses were administered approximately Q4W to both eyes; for Groups 4-9, a total of 3 intravitreal doses were administered approximately Q4W to both eyes. A terminal necropsy was performed approximately one week after the last dose (N=3 / sex / group), and a recovery necropsy was performed approximately 12 weeks after the last dose (2 / sex / group).
[0532] Perform the following assessments:
[0533] Safety assessments based on clinical signs, body weight, vital signs, electrocardiogram data (pre-dose end and end of treatment), blood pressure measurements (via tail cannula), clinical and anatomical pathology
[0534] Perform a comprehensive ophthalmologic examination including slit-lamp microscopy, indirect ophthalmoscopy, and intraocular pressure measurement regularly during dosing and recovery
[0535] Fundus photography, fluorescein angiography, and electroretinography before treatment, at study week 9 (all groups), week 26 (groups 1-3 only), and at the end of the recovery period
[0536] Blood and vitreous samples (at termination) for bioanalysis, ADA analysis, and toxicokinetic assessments
[0537] Table 13. Summary of study groups*
[0538]
[0539]
[0540] *Each of the formulations described is part of the present invention
[0541] It is expected that the formulations tested in any one or more of Group 1, Group 2, Group 3, Group 4, Group 5, Group 6, Group 7, Group 8 and / or Group 9 will have a safety profile comparable to EYLEA in cynomolgus monkeys as determined in the evaluations discussed above.
[0542] Example 13 : Stability study of products using VEGF trap.
[0543] Before filling, a formulation containing 114.3 mg / mL VEGF Trap (Aflibercept) and 10 mM histidine, pH 5.8, 5% sucrose, 0.03% polysorbate 20, 50 mM arginine-HCl was prepared in a LFH (laminar flow hood) using a 0.22 μm Durapore PVDF sterilizing filter. Clean, depyrogenated 3 mL type I Schott glass vials were filled with 0.3 mL of drug product and plugged with 13 mm serum bottle stoppers (S2-F451 4432 / 50B2-40). After storage at 37°C or 5°C, the purity of the samples was analyzed at different time points by size exclusion chromatography (SEC) to determine the presence (%) of high molecular weight species (HMW), low molecular weight species (LMW) and major peaks (main peaks); and the presence of particles of various sizes was determined by microflow imaging, HIAC liquid particle counting (by light shielding) and microscopy.
[0544] Figure 19 (AE) shows the stability and purity data after storage at 37°C, 25°C and 2-8°C. See also Tables 13-1 - 13-4.
[0545] Table 13-1. Size Exclusion Chromatography (SEC) Purity Analysis
[0546]
[0547]
[0548] Table 13-2: Microfluidic imaging / particles visible only under a microscope
[0549]
[0550] Table 13-3. Microscopic particulate matter / microscopic particles measured by light obscuration (HIAC)
[0551]
[0552] Table 13-4. Microscopic analysis of particles visible only under a microscope
[0553]
[0554] Embodiment 14 : Stability studies with varying VEGF trap concentrations.
[0555] The effect of different concentrations of VEGF Trap on the stability of four VEGF Trap (Aflibercept) ophthalmic drug formulations was studied. The concentration range was 80 to 140 mg / mL. The stability assessment was performed under storage conditions of 2-8°C. The drug (DP) was also incubated under stress (37°C) conditions. The four formulations evaluated in this stability study (each referred to herein as "CCC") are described in Table 14-1 below.
[0556] Before filling, about 27mL of each formulation was prepared in a LFH (laminar flow hood) using a 0.22μm Durapore PVDF sterilizing filter. Clean 2mL I-type Schott glass vials were filled and plugged with 13mm serum bottle stoppers (S2-F4514432 / 50B2-40). After storage at 37°C or 2-8°C, the purity of the samples was analyzed at different time points by size exclusion ultra-performance liquid chromatography (SE-UPLC) to determine the presence (%) of high molecular weight species (HMW) and major peaks (main peaks).
[0557] Figure 20 (AB) lists data showing the percentage of HMW after 6 months of incubation at 2-8°C or 37°C. See also Tables 14-2 and 14-3. When stored at 37°C and 5°C, these formulations showed a positive correlation between the rate of HMW formation and the concentration of VEGF Trap. The 140 mg / mL formulation showed the highest rate of %HMW species formation.
[0558] Table 14-1. Formulations tested.
[0559]
[0560] Table 14-2. SE-UPLC analysis (2-8°C)
[0561]
[0562] Table 14-3. SE-UPLC analysis (37°C)
[0563]
[0564]
[0565] Embodiment 15 : In the D,L-AAA model of persistent neovascular leakage, high-dose Eylea has a prolonged duration of action.
[0566] In this example, the effect of a four-fold increase in dose on the duration of action of aflibercept in inhibiting chronic retinal vascular leakage in the D,L-AAA model was determined.
[0567] The animals used were New Zealand white rabbits 3 months after DL-AAA (DL-α-aminoadipic acid) disease induction. The treatment groups were:
[0568] Placebo (preparation buffer) 50 mcl / eye; n = 6 eyes
[0569] Aflibercept 500 mcg / eye (in 50 mcl); n = 7 eyes
[0570] Aflibercept 2mcg / eye (in 50mcl); n=8 eyes
[0571] The formulation used in each treatment group was: 10 mM histidine, 8% sucrose, 0.03% PS20, pH
[0572] 5.8. Ophthalmological examinations performed at baseline and Weeks 1, 2, 4, 6, 7, 9, 10, 11, 13, and 18 were intraocular pressure (IOP), red-free (RF) imaging (to determine vascular morphology), fluorescein angiography (FA; to determine vascular leakage), optical coherence tomography (OCT; to determine vitreous inflammation). Serum (ADA) and plasma (drug levels) were collected at baseline and Weeks 1, 2, 4, 6, and 9.
[0573] The FA inspection data for each group are as follows Fig.21 These data suggest that the inhibition of vascular leakage in the retina of animals receiving the higher dose of aflibercept persisted longer than that of animals receiving the lower dose. At all sampling times up to 18 weeks post-dosing, the number of treated eyes with complete inhibition of vascular permeability was significantly increased in the 2 mg dose group.
Claims
1. An aqueous pharmaceutical preparation comprising: a VEGF receptor fusion protein, anti-VEGF antibody or antigen-binding fragment, or VEGF binding molecule at a concentration of at least about 100 mg / ml; About 5% sucrose Histidine buffer; and About 0.03% surfactant; Optionally, in combination with other therapeutic agents; wherein the pH of the formulation is from about 5.0 to about 6.
8.
2. The formulation according to claim 1, which is suitable for intravitreal administration.
3. The preparation according to any one of claims 1-2, further comprising sodium sulfate, sodium thiocyanate, glycine, NaCl, sodium aspartate, L-arginine and / or sodium glutamate.
4. The preparation according to any one of claims 1 to 3, wherein the VEGF receptor fusion protein or anti-VEGF antibody or antibody fragment or VEGF binding molecule is: (i) a VEGF receptor fusion protein comprising two polypeptides, the polypeptides comprising (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO: 2; (2) a VEGFR2 component comprising amino acids 130-231 of SEQ ID NO: 2; and (3) a multimerization component comprising amino acids 232-457 of SEQ ID NO: 2; (ii) a VEGF receptor fusion protein comprising two polypeptides comprising the immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and the Ig domain 3 of a second VEGF receptor, and a multimeric component; (iii) a VEGF receptor fusion protein comprising two polypeptides, the polypeptide comprising an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, an Ig domain 4 of the second VEGF receptor, and a multimeric component; (iv) a VEGF receptor fusion protein comprising two polypeptides, the polypeptides comprising the immunoglobulin-like (Ig) domain 2 of VEGFR1, the Ig domain 3 of VEGFR2, and a multimeric component; (v) a VEGF receptor fusion protein comprising two polypeptides, the polypeptides comprising immunoglobulin-like (Ig) domain 2 of VEGFR1, Ig domain 3 of VEGFR2, Ig domain 4 of VEGFR2 and a multimeric component; (vi) a VEGF receptor fusion protein comprising two VEGFR1R2-FcΔC1(a) polypeptides encoded by the nucleic acid sequence of SEQ ID NO: 1; or (vii) selected from the group consisting of: bevacizumab, ranibizumab, pegaptanib, brolucizumab, anti-VEGF DARPin, and a bispecific anti-VEGF / ANG2 antibody.
5. The formulation according to any one of claims 1 to 4, wherein the VEGF receptor fusion protein or anti-VEGF antibody or antibody fragment or VEGF binding molecule is a VEGF receptor fusion protein selected from aflibercept and conbercept.
6. The formulation of any one of claims 1-5, wherein the VEGF receptor fusion protein or anti-VEGF antibody or antibody fragment or VEGF binding molecule is a VEGF receptor fusion protein at a concentration of about 41 to about 275 mg / ml.
7. The preparation according to any one of claims 1-6, wherein the VEGF receptor fusion protein or anti-VEGF antibody or antibody fragment or VEGF binding molecule is a VEGF receptor fusion protein, which is a VEGF receptor fusion protein at a concentration of: About 100 mg / ml; About 111.5 mg / ml; About 112.0 mg / ml; About 113.3 mg / ml; About 114.3 mg / ml; About 115.6 mg / ml; About 116.3 mg / ml; About 120 mg / ml; About 133 mg / ml; About 140 mg / ml; About 150 mg / ml; About 200 mg / ml; About 250 mg / ml; It contains about 4 mg of VEGF receptor fusion protein in about 100 μl or less, about 70 μl or less, about 75 μl or less, about 50 μl or less, or about 60 μl or less; It contains about 6 mg of VEGF receptor fusion protein in about 100 μl or less, about 70 μl or less, about 75 μl or less, about 50 μl or less, or about 60 μl or less; It contains about 8 mg of VEGF receptor fusion protein in about 100 μl or less, about 70 μl or less, about 75 μl or less, about 50 μl or less, or about 60 μl or less; or - It contains about 10 mg of VEGF receptor fusion protein in about 100 μl or less, about 70 μl or less, about 75 μl or less, about 50 μl or less, or about 60 μl or less.
8. The formulation according to any one of claims 1 to 7, wherein: (i) an osmolality of about 299 to about 506 mmol / kg; and / or (ii) The viscosity is about 6-15 cP at 20°C.
9. The formulation of any one of claims 1-8, wherein the pH is 5.8 to 6.
5.
10. The formulation of claim 9, wherein the pH is about 5.
8.
11. The formulation of any one of claims 1-10, wherein the surfactant is a nonionic surfactant.
12. The formulation of claim 11, wherein the nonionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80, poloxamer 188, polyethylene glycol 3350, and mixtures thereof.
13. The formulation of any one of claims 1-12, wherein the histidine is histidine hydrochloride.
14. The formulation of claim 13, comprising about 10 mM to 20 mM histidine hydrochloride.
15. The formulation according to any one of claims 1 to 14, comprising a heat stabilizer which is a sugar.
16. The formulation of claim 15, wherein the sugar is sucrose, mannitol, sorbitol or trehalose.
17. The formulation of any one of claims 15-16, comprising about 2.5% (w / v), about 5% (w / v), about 8% (w / v), about 10% (w / v), or about 20% (w / v) sucrose.
18. The formulation of any one of claims 1-17, comprising a surfactant at a concentration of about 0.03% (w / v).
19. The preparation according to any one of claims 1 to 18, comprising L-arginine hydrochloride.
20. The formulation of any one of claims 1-19, wherein the VEGF receptor fusion protein or anti-VEGF antibody or antibody fragment or VEGF binding molecule is a VEGF receptor fusion protein having less than about 3.5% high molecular weight species immediately after manufacture and purification and / or having less than or equal to about 6% high molecular weight species after storage at about 2-8°C for about 24 months.
21. A formulation comprising a component selected from the group consisting of: Formulation A: 80 mg / ml aflibercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation B: 80 mg / ml aflibercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation C: 80 mg / ml aflibercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation D: 80 mg / ml aflibercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 6.2; Formulation E: 80 mg / ml aflibercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation F: 80 mg / ml aflibercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation G: 80 mg / ml aflibercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation H: 80 mg / ml aflibercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation I: 80 mg / ml aflibercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation J: 80 mg / ml aflibercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation K: 80 mg / ml aflibercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation L: 80 mg / ml aflibercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation M: 150 mg / ml aflibercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation N: 150 mg / ml aflibercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation O: 150 mg / ml aflibercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation P: 150 mg / ml aflibercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 6.2; Formulation Q: 150 mg / ml aflibercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation R: 150 mg / ml aflibercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation S: 150 mg / ml aflibercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation T: 150 mg / ml aflibercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation U: 150 mg / ml aflibercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation V: 150 mg / ml aflibercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation W: 150 mg / ml aflibercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation X: 150 mg / ml aflibercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation Y: 80 mg / ml Conbercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation Z: 80 mg / ml Conbercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation AA: 80 mg / ml Conbercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation BB: 80 mg / ml Conbercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 6.2; Formulation CC: 80 mg / ml Conbercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation DD: 80 mg / ml Conbercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation EE: 80 mg / ml Conbercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation FF: 80 mg / ml Conbercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation GG: 80 mg / ml Conbercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation HH: 80 mg / ml Conbercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation II: 80 mg / ml Conbercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation JJ: 80 mg / ml Conbercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation KK: 150 mg / ml Conbercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation LL: 150 mg / ml Conbercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation MM: 150 mg / ml Conbercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation NN: 150 mg / ml Conbercept, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 6.2; Formulation OO: 150 mg / ml Conbercept, 10 mM phosphate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation PP: 150 mg / ml Conbercept, 10 mM citrate-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 80, and 40 mM sodium chloride, pH 5.8 to 6.2; Formulation QQ: 150 mg / ml Conbercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation RR: 150 mg / ml Conbercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation SS: 150 mg / ml Conbercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 20, pH 5.8 to 6.2; Formulation TT: 150 mg / ml Conbercept, 10 mM histidine-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation UU: 150 mg / ml Conbercept, 10 mM phosphate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation VV: 150 mg / ml Conbercept, 10 mM citrate-based buffer, 8% (w / v) sucrose, and 0.03% (w / v) polysorbate 80, pH 5.8 to 6.2; Formulation WW: 140 mg / ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM taurine, pH 5.8; Formulation XX: 140 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 4% (w / v) proline, 0.03% (w / v) polysorbate 20, and 50 mM arginine hydrochloride, pH 5.8; Formulation YY: 140 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 2.5% (w / v) sucrose, 2.0% (w / v) proline, 0.03% (w / v) polysorbate 20 and 50 mM taurine, pH 5.8; Formulation ZZ: 140 mg / ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 2.5% (w / v) sucrose, 2.0% (w / v) proline, 0.03% (w / v) polysorbate 20 and 50 mM arginine hydrochloride, pH 5.8; Formulation AAA: 140 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM PSA, pH 5.8; Formulation BBB: 140 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 2.5% (w / v) sucrose, 2.0% (w / v) proline, 0.03% (w / v) polysorbate 20, and 50 mM PSA, pH 5.8; Formulation CCC: 80, 100, 120, or 140 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM arginine hydrochloride, pH 5.8; Formulation DDD: 140 mg / ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 4% (w / v) proline, 0.03% (w / v) polysorbate 20, and 50 mM PSA, pH 5.8; Formulation EEE: 140 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w / v) sucrose and 0.03% (w / v) polysorbate 20, and no thermal stabilizer, pH 5.8; Formulation FFF: 140 mg / ml VEGF receptor fusion protein, 10 mM sodium phosphate, 5% (w / v) sucrose and 0.03% polysorbate 20, pH 6.2; Formulation GGG: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium sulfate; Formulation HHH: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium thiocyanate; Formulation III: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 40 mM sodium citrate; Formulation JJJ: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose, 0.03% polysorbate 20; 50 mM glycine; Formulation KKK: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose, 0.03% polysorbate 20; 50 mM sodium chloride; Formulation LLL: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM lysine; Formulation MMM: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate; Formulation NNN: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate; Formulation OOO: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium citrate; 50 mM arginine hydrochloride; Formulation PPP: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM glycine; 50 mM arginine hydrochloride; Formulation QQQ: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate; 50 mM arginine hydrochloride; Formulation RRR: 140 mg / ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate; 50 mM arginine hydrochloride; Formulation SSS: 140 mg / ml VEGF receptor fusion protein; 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 10 mM L-arginine hydrochloride; Preparation TTT: 140 mg / ml VEGF receptor fusion protein; 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 100 mM L-arginine hydrochloride; Formulation UUU: 30 mg / ml VEGF receptor fusion protein, 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2; Formulation VVV: 30 mg / ml VEGF receptor fusion protein, 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2; Formulation WWW: 60 mg / ml VEGF receptor fusion protein, 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2; Formulation XXX: 60 mg / ml VEGF receptor fusion protein, 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2; Formulation YYY: 120 mg / ml VEGF receptor fusion protein, 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2; Formulation ZZZ: 120 mg / ml VEGF receptor fusion protein, 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2; Formulation AAAA: 120 mg / ml VEGF receptor fusion protein, 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, 50 mM NaCl, pH 6.2; Formulation BBBB: 120 mg / ml VEGF receptor fusion protein, 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, 50 mM NaCl, pH 6.2; Formulation CCCC: 140 mg / ml VEGF receptor fusion protein, 10 mM sodium phosphate, 5% sucrose, 40 mM sodium chloride, 0.03% PS20, pH 6.2; Formulation DDDD: 80.0 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20 and 50 mM L-arginine monohydrochloride, pH 5.8; Formulation EEEE: 120.0 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20 and 50 mM L-arginine monohydrochloride, pH 5.8; Formulation FFFF: 113.3 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20 and 50 mM L-arginine monohydrochloride, pH 5.8; Formulation GGGG: 114.3 mg / ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM L-arginine monohydrochloride, pH 5.8; Formulation HHHH: 100.0 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM L-arginine monohydrochloride, pH 5.8; and Formulation IIII: 133.3 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM L-arginine monohydrochloride, pH 5.8; Formulation JJJJ: 150 mg / ml aflibercept, 10 mM sodium phosphate, 8% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM arginine hydrochloride, pH 6.2; Formulation KKKK: 114.3 mg / ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, and 50 mM L-arginine monohydrochloride, pH 5.8; Formulation LLLL: 90 mg / ml VEGF receptor fusion protein, 10 mM histidine, 5% (w / v) sucrose, 0.03% (w / v) polysorbate 20, pH 5.75; and Formulation MMMM: 90 mg / ml VEGF receptor fusion protein, 10 mM histidine, 7% (w / v) sucrose, 0.03% (w / v) polysorbate 20, pH 5.
75.
22. The formulation of claim 21, wherein the VEGF receptor fusion protein is aflibercept or conbercept.
23. The formulation of any one of claims 21-22, wherein the VEGF receptor fusion protein has less than about 3.5% high molecular weight species immediately after manufacture and purification and / or has less than or equal to about 6% high molecular weight species after storage for about 24 months at about 2-8°C.
24. A container or injection device comprising the formulation of any one of claims 1-23.
25. The container or injection device according to claim 24, which is a vial, a syringe, an autoinjector or a pre-filled syringe.
26. A method of preparing the formulation of any one of claims 1-23 comprising combining the components of the formulation into a single composition.
27. The method of claim 26, further comprising loading a volume of the formulation into a syringe.
28. A formulation which is the product of the method of any one of claims 26-27.
29. A method of administering the formulation of any one of claims 1-22 and 27 to a subject, comprising intraocularly injecting the formulation into an eye of the subject.
30. A method of treating an angiogenic eye disease in a subject in need thereof, comprising administering to an eye of the subject an intraocular injection of greater than about 2 mg of a VEGF receptor fusion protein.
31. The method of claim 30, comprising administering about 4 mg, about 6 mg, about 8 mg, or about 10 mg of the VEGF receptor fusion protein to an eye of the subject.
32. A method for treating angiogenic eye disease in a subject in need thereof, the method comprising intraocularly injecting greater than about 2 mg of a VEGF receptor fusion protein of any one of claims 1-23 and 28 into an eye of the subject.
33. The method of claim 32, comprising injecting about 4 mg, about 6 mg, about 8 mg, or about 10 mg of the VEGF receptor fusion protein into the eye of the subject.
34. The method of any one of claims 30-33, wherein the intraocular injection is an intravitreal injection.
35. The method of any one of claims 30-34, wherein the vascular eye disease is age-related macular degeneration (wet), macular edema, macular edema following retinal vein occlusion, retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular edema (DME), choroidal neovascularization (CNV), iris neovascularization, neovascular glaucoma, post-operative fibrosis of glaucoma, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal neovascularization, vitreous neovascularization, pannus, pterygium, vascular retinopathy, diabetic retinopathy, non-proliferative diabetic retinopathy and / or proliferative diabetic retinopathy.
36. The method of any one of claims 30-35, wherein the VEGF receptor fusion protein is administered in about 100 microliters or less, about 90 microliters, about 80 microliters, about 75 microliters, about 70 microliters, about 60 microliters, or about 50 microliters.
37. The method of any one of claims 30-36, wherein the VEGF receptor fusion protein is contained in a formulation comprising: about 5% sucrose; histidine buffer; and about 0.03% surfactant.
38. The method of any one of claims 30-37, wherein about 2.0 mg of the VEGF receptor fusion protein is injected once every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 weeks.
Citation Information
Patent Citations
Pre-Filled Plastic Syringe Containing a VEGF Antagonist
US20170232199A1
Polyarylene Sulfide Composition with Improved Adhesion to Metal Components
US20190031879A1
Method of treating cancer with a VEGF antagonist and an anti-proliferative agent
US7354579B2
VEGF-binding fusion proteins and nucleic acids encoding the same
US7396664B2
VEGF traps and therapeutic uses thereof
WO2005000895A2
